selected publications
-
academic article
- Yap MLMcFadyen JDWang XZiegler MChen YCWillcox ANowell CJScott AMSloan EKHogarth PMPietersz GAPeter K. Activated platelets in the tumor microenvironment for targeting of antibody-drug conjugates to tumors and metastases. Theranostics. 9:1154-1169. 2019
- Lassman ABVan Den Bent MJGan HKReardon DAKumthekar PButowski NLwin ZMikkelsen TNabors LBPapadopoulos KPPenas-Prado MSimes JWheeler HWalbert TScott AMGomez ELee HJRoberts-Rapp LXiong HAnsell PJBain EHolen KDMaag DMerrell R. OUP accepted manuscript. Neuro-Oncology. 21:106-114. 2019
- Parslow ACClayton AHALock PScott AM. Confocal microscopy reveals cell surface receptor aggregation through image correlation spectroscopy. Journal of Visualized Experiments. 2018. 2018
- Lau LFMurone CWilliams DSStandish RLee STChristophi CScott AMMuralidharan V. Metabolic response evaluation for colorectal liver metastases and correlation to pathologic response and tumour markers. ANZ Journal of Surgery. 88:E108-E113. 2018
- Emmett LMetser UBauman GHicks RJWeickhardt ADavis IDPunwani SPond GRChua SS-CHo BJohnston EPouliot FScott A. A Prospective, Multi-site, International Comparison of F-18 fluoro-methyl-choline, multi-parametric magnetic resonance and Ga-68 HBED-CC (PSMA-11) in men with High-Risk Features and Biochemical Failure after Radical Prostatectomy: Clinical Performance and Patient Outcomes. Journal of Nuclear Medicine. 2018
- Phillips ACBoghaert ERVaidya KSFalls HDMitten MJDeVries PJBenatuil LHsieh C-MMeulbroek JAPanchal SCBuchanan FGDurbin KRVoorbach MJReuter DRMudd SRLoberg LIRalston SLCao DGan HKScott AMReilly EB. Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate. Molecular Cancer Therapeutics. 17:795-805. 2018
- Li HZeitelhofer MNilsson ILiu XAllan LGloria BPerani AMurone CCatimel BNeville AMScott FEScott AMEriksson U. Development of monoclonal anti-PDGF-CC antibodies as tools for investigating human tissue expression and for blocking PDGF-CC induced PDGFRα signalling in vivo. PLoS ONE. 13:1-20. 2018
- Binder ZAThorne AHBakas SWileyto EPBilello MAkbari HRathore SHa SMZhang LFerguson CJDahiya SBi WLReardon DAIdbaih AFelsberg JHentschel BWeller MBagley SJMorrissette JJDNasrallah MPMa JZanca CScott AMOrellana LDavatzikos CFurnari FBO'Rourke DM. Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development. Cancer Cell. 34:163-177.e7. 2018
- Owen CEPoon AMTLee STYap LPZwar RBMcMenamin CMLam SKLLiew DFLPathmaraj KKemp AScott AMBuchanan RRC. Fusion of positron emission tomography/computed tomography with magnetic resonance imaging reveals hamstring peritendonitis in polymyalgia rheumatica. Rheumatology. 57:345-353. 2018
- Burvenich IJGFarrugia WLiu ZMakris DKing DGloria BPerani AAllan LCScott AMRamsland PA. Global conformational changes in IgG-Fc upon mutation of the FcRn-binding site are not associated with altered antibody-dependent effector functions. Biochemical Journal. 475:2179-2190. 2018
- Ayati NLee STZakavi RPathmaraj KAl-Qatawna LPoon AScott AM. Long-Acting Somatostatin Analog Therapy Differentially Alters 68 Ga-DOTATATE Uptake in Normal Tissues Compared with Primary Tumors and Metastatic Lesions. Journal of Nuclear Medicine. 59:223-227. 2018
- Nadebaum DLee SNikfarjam MScott AM. Metastatic clear cell renal cell carcinoma demonstrating intense uptake on 68 Ga-DOTATATE positron emission tomography: Three case reports and a review of the literature. World Journal of Nuclear Medicine. 17:195-197. 2018
- Roswall PBocci MBartoschek MLi HKristiansen GJansson SLehn SSjölund JReid SLarsson CEriksson PAnderberg CCortez ESaal LHOrsmark-Pietras CCordero EHaller BKHäkkinen JBurvenich IJGLim EOrimo AHöglund MRydén LMoch HScott AMEriksson UPietras K. Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signaling. Nature Medicine. 24:463-473. 2018
- McKay MJTaubman KLForoudi FLee STScott AM. Molecular Imaging Using PET/CT for Radiation Therapy Planning for Adult Cancers: Current Status and Expanding Applications. International Journal of Radiation: Oncology - Biology - Physics. 102:783-791. 2018
- Burvenich IJGParakh SLee F-TGuo NLiu ZGan HKRigopoulos AO'Keefe GJGong SJGoh YWTochon-Danguy HScott FEKotsuma MHirotani KSenaldi GScott AM. Molecular imaging of T cell co-regulator factor B7-H3 with Zr-89-DS-5573a. Theranostics. 8:4199-4209. 2018
- Hafeez UGan HKScott AM. Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases. Current Opinion in Pharmacology. 41:114-121. 2018
- Zeitelhofer MLi HAdzemovic MZNilsson IMuhl LScott AMEriksson U. Preclinical toxicological assessment of a novel monoclonal antibody targeting human platelet-derived growth factor CC (PDGF-CC) in PDGF-CChum mice. PLoS ONE. 13:1-16. 2018
- Burvenich IJGParakh SParslow ACLee STGan HKScott AM. Receptor occupancy imaging studies in oncology drug development. American Association of Pharmaceutical Scientists (AAPS) Journal. 20:1-16. 2018
- Vargas HAKramer GMScott AMWeickhardt AMeier AAParada NBeattie BJHumm JLStaton KDZanzonico PBLyashchenko SKLewis JSYaqub MSosa REvan den Eertwegh AJDavis IDAckermann UPathmaraj KSchuit RCWindhorst ADChua SWeber WALarson SMScher HILammertsma AAHoekstra OMorris MJ. Reproducibility and Repeatability of Semiquantitative 18F-Fluorodihydrotestosterone Uptake Metrics in Castration-Resistant Prostate Cancer Metastases: A Prospective Multicenter Study. Journal of Nuclear Medicine. 59:1516-1523. 2018
- Gan HKReardon DALassman ABMerrell Rvan den Bent MButowski NLwin ZWheeler HFichtel LScott AMGomez EJFischer JMandich HXiong HLee H-JMunasinghe WPRoberts-Rapp LAAnsell PJHolen KDKumthekar P. Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma. Neuro-Oncology. 20:838-847. 2018
- Roach PJFrancis REmmett LHsiao EKneebone AHruby GEade TNguyen QAThompson BDCusick TMcCarthy MTang CHo BStricker PDScott AM. The Impact of 68 Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study. Journal of Nuclear Medicine. 59:82-88. 2018
- Chang AYDao TGejman RSJarvis CAScott ADubrovsky LMathias MDKorontsvit TZakhaleva VCurcio MHendrickson RCLiu CScheinberg DA. A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens. Journal of Clinical Investigation. 127:3557-3557. 2017
- Chang AYDao TGejman RSJarvis CAScott ADubrovsky LMathias MDKorontsvit TZakhaleva VCurcio MHendrickson RCLiu CScheinberg DA. A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens. Journal of Clinical Investigation. 127:2705-2718. 2017
- Gan HKvan den Bent MLassman ABReardon DAScott AM. Antibody–drug conjugates in glioblastoma therapy: the right drugs to the right cells. Nature Reviews Clinical Oncology. 14:695-707. 2017
- Björnmalm MThurecht KJMichael MScott AMCaruso F. Bridging Bio–Nano Science and Cancer Nanomedicine. ACS Nano. 11:9594-9613. 2017
- Philip MFairchild LSun LHorste ELCamara SShakiba MScott ACViale ALauer PMerghoub THellmann MDWolchok JDLeslie CSSchietinger A. Chromatin states define tumour-specific T cell dysfunction and reprogramming. Nature. 545:452-456. 2017
- Laval MMarshall KMSachinidis JScott AEutick MBaldwin GS. Complexes of gastrin with In3+, Ru3+ or Ga3+ ions are not recognised by the cholecystokinin 2 receptor. Journal of Biological Inorganic Chemistry. 22:999-1006. 2017
- Reardon DALassman ABvan den Bent MKumthekar PMerrell RScott AMFichtel LSulman EPGomez EFischer JLee H-JMunasinghe WXiong HMandich HRoberts-Rapp LAnsell PHolen KDGan HK. Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.. Neuro-Oncology. 19:965-975. 2017
- van den Bent MGan HKLassman ABKumthekar PMerrell RButowski NLwin ZMikkelsen TNabors LBPapadopoulos KPPenas-Prado MSimes JWheeler HWalbert TScott AMGomez ELee H-JRoberts-Rapp LXiong HBain EAnsell PJHolen KDMaag DReardon DA. Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study. Cancer Chemotherapy and Pharmacology. 80:1209-1217. 2017
- Charmsaz SAl-Ejeh FYeadon TMMiller KJSmith FMStringer BWMoore ASLee F-TCooper LTStylianou CYarranton GTWoronicz JScott AMLackmann MBoyd AW. EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia. Leukemia. 31:1779-1787. 2017
- Parakh SGan HKParslow ACBurvenich IJGBurgess AWScott AM. Evolution of anti-HER2 therapies for cancer treatment. Cancer Treatment Reviews. 59:1-21. 2017
- Yeung YLau DKChionh FTran HTse JWTWeickhardt AJNikfarjam MScott AMTebbutt NCMariadason JM. K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines. Molecular Oncology. 11:1130-1142. 2017
- Orcutt KDAdams GPWu AMSilva MDHarwell CHoppin JMatsumura MKotsuma MGreenberg JScott AMBeckman RA. Molecular simulation of receptor occupancy and tumor penetration of an antibody and smaller scaffolds: application to molecular imaging. Molecular Imaging and Biology. 19:656-664. 2017
- Di Biase MAZalesky AO'Keefe GLaskaris LBaune BTWeickert CSOlver JMcGorry PDAmminger GPNelson BScott AMHickie IBanati RTurkheimer FYaqub MEverall IPPantelis CCropley V. PET imaging of putative microglial activation in individuals at ultra-high risk for psychosis, recently diagnosed and chronically ill with schizophrenia. Translational Psychiatry. 7:1-8. 2017
- Rivalland GScott AMJohn T. Standard of care in immunotherapy trials: challenges and considerations. Human Vaccines and Immunotherapeutics. 13:2164-2178. 2017
- Charmsaz SScott AMBoyd AW. Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors. Experimental Hematology. 54:31-39. 2017
- Eissmann MAtapattu LSaha NChheang CEissman MFXu KVail MEHii LLlerena CLiu ZHorvay KAbud HEKusebauch UMoritz RLDing B-SCao ZRafii SErnst MScott AMNikolov DBLackmann MJanes PW. An activated form of ADAM10 is tumor selective and regulates cancer stem-like cells and tumor growth. Journal of Experimental Medicine. 213:1741-1757. 2016
- Parslow ACParakh SLee F-TGan HKScott AM. Antibody-Drug Conjugates for Cancer Therapy. Biomedicines. 4:1-17. 2016
- Parakh SParslow ACGan HKScott AM. Antibody-mediated delivery of therapeutics for cancer therapy. Expert Opinion on Drug Delivery. 13:401-419. 2016
- Jahani-Asl AYin HSoleimani VDHaque TLuchman HAChang NCSincennes MCPuram SVScott AMLorimer IAJPerkins TJLigon KLWeiss SRudnicki MABonni A. Control of glioblastoma tumorigenesis by feed-forward cytokine signaling. Nature Neuroscience. 19. 2016
- Burvenich IJGFarrugia WLee FTCatimel BLiu ZMakris DCao DO'Keefe GJBrechbiel MWKing DSpirkoska VAllan LCRamsland PAScott AM. Cross-species analysis of Fc engineered anti-Lewis-Y human IgG1 variants in human neonatal receptor transgenic mice reveal importance of S254 and Y436 in binding human neonatal Fc receptor. mAbs. 8:775-786. 2016
- Gan HKBurgess AWParslow ACScott AM. Dual targeting of EGFR: Ready for prime time?. Translational Cancer Research. 5:S18-S21. 2016
- Burvenich IJGLee F-TO'Keefe GJMakris DCao DGong SRigopoulos AAllan LCBrechbiel MWLiu ZRamsland PAScott AM. Engineering anti-Lewis-Y hu3S193 antibodies with improved therapeutic ratio for radioimmunotherapy of epithelial cancers. EJNMMI Research. 6:1-13. 2016
- Laurens EYeoh SDRigopoulos AO'Keefe GJTochon-Danguy HJChong LWWhite JMScott AMAckermann U. Fluorine-18 radiolabeling of a nitrophenyl sulfoxide and its evaluation in an SK-RC-52 model of tumor hypoxia. Journal of Labelled Compounds and Radiopharmaceuticals. 59:416-423. 2016
- Ackerman UAckermann ULewis JSYoung KMorris MJWeickhardt ADavis IDScott AM. Fully automated synthesis of [18F]fluoro-dihydrotestosterone ([18F]FDHT) using the FlexLab module. Journal of Labelled Compounds and Radiopharmaceuticals. 59:424-428. 2016
- Higginbotham JNZhang QJeppesen DKScott AMManning HCOchieng JFranklin JLCoffey RJ. Identification and characterization of EGF receptor in individual exosomes by fluorescence-activated vesicle sorting. Journal of Extracellular Vesicles. 5. 2016
- Burvenich IJGLee F-TGuo NGan HKRigopoulos AParslow ACO'Keefe GJGong SJTochon-Danguy HRudd SEDormelly PSKotsuma MOhtsuka TSenaldi GScott AM. In vitro and in vivo evaluation of 89Zr-DS-8273a as a theranostic for anti-death receptor 5 therapy. Theranostics. 6:2225-2234. 2016
- Lee FTBurvenich IJGGuo NKocovski PTochon-Danguy HAckermann UO'Keefe GJGong SRigopoulos ALiu ZGan HKScott AM. L-Tyrosine Confers Residualizing Properties to a D-Amino Acid-Rich Residualizing Peptide for Radioiodination of Internalizing Antibodies. Molecular Imaging. 15:1-9. 2016
- Burvenich IJGParakh SGan HKLee F-TGuo NRigopoulos ALee S-TGong SO'Keefe GJTochon-Danguy HKotsuma MHasegawa JSenaldi GScott AM. Molecular Imaging and Quantitation of EphA2 Expression in Xenograft Models with Zr-89-DS-8895a. Journal of Nuclear Medicine. 57:974-980. 2016
- Fahey FHBom HH-SChiti AChoi YYHuang GLassmann MLaurin NMut FNunez-Miller RO'Keeffe DPradhan PScott AMSong SSoni NUchiyama MVargas L. Standardization of administered activities in pediatric nuclear medicine: a report of the first Nuclear Medicine Global Initiative project, part 2 - current standards and the path toward global standardization. Journal of Nuclear Medicine. 57:1148-1157. 2016
- Chia PLRussell PAScott AMJohn T. Targeting the vasculature: anti-angiogenic agents for malignant mesothelioma. Expert Review of Anticancer Therapy: an essential contribution to decision making in cancer care. 16:1235-1245. 2016
- Solomon BJDesai JRosenthal MMcArthur GAPattison STPattison SLMacDiarmid JBrahmbhatt HScott AM. A First-Time-In-Human Phase i Clinical Trial of Bispecific Antibody-Targeted, Paclitaxel-Packaged Bacterial Minicells. PLoS ONE. 10. 2015
- Reilly EBPhillips ACBuchanan FGKingsbury GZhang YMeulbroek JACole TBDevries PJFalls HDBeam CGu JDigiammarino ELPalma JPDonawho CKGoodwin NCScott AM. Characterization of ABT-806, a humanized tumor-specific anti-EGFR monoclonal antibody. Molecular Cancer Therapeutics. 14:1411-1451. 2015
- Chang JHLim Joon DDavis IDLee STHiew CYEsler SGong SJWada MClouston DO'Sullivan RGoh YPBolton DScott AMKhoo V. Comparison of [<sup>11</sup>C]choline positron emission tomography with T2- and diffusion-weighted magnetic resonance imaging for delineating malignant intraprostatic lesions. International Journal of Radiation: Oncology - Biology - Physics. 92:438-445. 2015
- Baird SKAllan LRenner CScott FEScott AM. Fibroblast activation protein increases metastatic potential of fibrosarcoma line HT1080 through upregulation of integrin-mediated signaling pathways. Clinical and Experimental Metastasis. 32:507-516. 2015
- Whittle JRLickliter JDGan HKScott AMSimes JSolomon BJMacDiarmid JABrahmbhatt HRosenthal MA. First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma. Journal of Clinical Neuroscience. 22:1889-1894. 2015
- Williams BBTebbutt NCBuchert MPutoczki TLDoggett KBao SJohnstone CNMasson FHollande FBurgess AWScott AMErnst MHeath JK. Glycoprotein A33 deficiency: A new mouse model of impaired intestinal epithelial barrier function and inflammatory disease. Disease Models and Mechanisms. 8:805-815. 2015
- Baird SKRigopoulos ACao DAllan LRenner CScott FEScott AM. Integral membrane protease fibroblast activation protein sensitizes fibrosarcoma to chemotherapy and alters cell death mechanisms. Apoptosis: an international journal on programmed cell death. 20:1483-1498. 2015
- Greening DWLee STJi HSimpson RJRigopoulos AMurone CFang CGong SO'Keefe GScott AM. Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathways. Oncotarget. 6:38166-38180. 2015
- Zanzonico PCarrasquillo JAPandit-Taskar NO Donoghue JAHumm JLSmith-Jones PRuan SDivgi CScott AMKemeny NEFong YWong DScheinberg DRitter GJungbluth AOld LJLarson SM. PET-based compartmental modeling of 124I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer. European Journal of Nuclear Medicine and Molecular Imaging. 42:1700-1706. 2015
- Zanzonico PCarrasquillo JAPandit-Taskar NO'Donoghue JAHumm JLSmith-Jones PRuan SDivgi CScott AMKemeny NEFong YWong DScheinberg DRitter GJungbluth AOld LJLarson SM. PET-based compartmental modeling of I-124-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer. European Journal of Nuclear Medicine and Molecular Imaging. 42:1700-1706. 2015
- Ciprotti MTebbutt NCLee F-TLee S-TGan HKMcKee DCO'Keefe GJGong SJChong GHopkins WChappell BScott FEBrechbiel MWTse ANJansen MMatsumura MKotsuma MWatanabe RVenhaus RBeckman RAGreenberg JScott AM. Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology. 33:2609-2616. 2015
- Kao YHGoodwin MLee STLichtenstein MScott AM. Scientific basis of personalised tomographic radiation planning for radioembolisation: A form of brachytherapy planning. Journal of Medical Imaging and Radiation Oncology. 59:617-618. 2015
- Fahey FHBom HHSChiti AChoi YYHuang GLassmann MLaurin NMut FNuñez-Miller RO'Keeffe DPradhan PScott AMSong SSoni NUchiyama MVargas L. Standardization of Administered activities in pediatric nuclear medicine: A report of the first Nuclear Medicine Global Initiative project, part 1 - Statement of the Issue and a review of available resources. Journal of Nuclear Medicine. 56:646-651. 2015
- Dingjan TSpendlove IDurrant LGScott AMYuriev ERamsland PA. Structural biology of antibody recognition of carbohydrate epitopes and potential uses for targeted cancer immunotherapies. Molecular Immunology. 67:75-88. 2015
- Johnston AJMurphy KTJenkinson LLaine DEmmrich KFaou PWeston RJayatilleke KMSchloegel JTalbo GCasey JLLevina VWong WW-LDillon HSahay THoogenraad JAnderton HHall CSchneider PTanzer MFoley MScott AMGregorevic PLiu SYBurkly LCLynch GSSilke JHoogenraad NJ. Targeting of Fn14 Prevents Cancer-Induced Cachexia and Prolongs Survival. Cell. 162:1365-1378. 2015
- Lee STScott AM. The current role of pet/ct in radiotherapy planning. Current Radiopharmaceuticals. 8:38-44. 2015
- Dao TPankov DScott AKorontsvit TZakhaleva VXu YXiang JYan SDe Morais Guerreiro MDVeomett NDubrovsky LCurcio MDoubrovina EPonomarev VLiu CO'Reilly RJScheinberg DA. Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1. Nature Biotechnology. 33:1079-1086. 2015
- Ackerman UNorth AJHayne DJSchieber CPrice KWhite ARCrouch PJRigopoulos AO'Keefe GJTochon-Danguy HScott AMWhite JMAckermann UDonnelly PS. Toward Hypoxia-Selective Rhenium and Technetium Tricarbonyl Complexes. Inorganic Chemistry: including bioinorganic chemistry. 54:9594-9610. 2015
- Weickhardt AJWilliams DSLee CKChionh FSimes JMurone CWilson KParry MMAsadi KScott AMPunt CJANagtegaal IDPrice TJMariadason JMTebbutt NC. Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer. British Journal of Cancer. 113:37-45. 2015
- Mertens LSMir MCScott AMLee STFioole-Bruining AVegt EVogel WVManecksha RBolton DDavies IHorenblas SVan Rhijn BWGLawrentschuk N. 18F-fluorodeoxyglucose-positron emission tomography/computed tomography aids staging and predicts mortality in patients with muscle-invasive bladder cancer. Urology. 83:393-399. 2014
- Dubrovsky LPankov DBrea EJDao TScott AYan SO'Reilly RJLiu CScheinberg DA. A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias. Blood. 123:3296-3304. 2014
- Ardipradja KYeoh SDAlt KO'Keefe GRigopoulos AHowells DWScott AMPeter KAckerman UHagemeyer CE. Detection of activated platelets in a mouse model of carotid artery thrombosis with 18F-labeled single-chain antibodies. Nuclear Medicine and Biology. 41:229-237. 2014
- Chang JHLim Joon DLee STHiew CYEsler SGong SJWada MClouston DO'Sullivan RGoh YPTochon-Danguy HChan JGBolton DScott AMKhoo VDavis ID. Diffusion-weighted MRI, 11C-choline PET and 18F- fluorodeoxyglucose PET for predicting the Gleason score in prostate carcinoma. European Radiology. 24:715-722. 2014
- Janes PWSlape CIFarnsworth RHAtapattu LScott AMVail ME. EphA3 biology and cancer. Growth Factors. 32:176-189. 2014
- Tan GJSBerlangieri SULee STScott AM. FDG PET/CT in the liver: lesions mimicking malignancies. Abdominal Imaging. 39:187-195. 2014
- Ackermann UPlougastel LWichmann CGoh YWYeoh SDPoniger SSTochon-Danguy HJScott AM. Fully automated synthesis and coupling of [18F]FBEM to glutathione using the iPHASE FlexLab module. Journal of Labelled Compounds and Radiopharmaceuticals. 57:115-120. 2014
- To CFarnsworth RHVail MEChheang CGargett CEMurone CLlerena CMajor ATScott AMJanes PWLackmann M. Hypoxia-controlled EphA3 marks a human endometrium-derived multipotent mesenchymal stromal cell that supports vascular growth. PLoS ONE. 9. 2014
- Ackermann UPlougastel LGoh YWYeoh SDScott AM. Improved synthesis of [18F]FLETT via a fully automated vacuum distillation method for [18F]2-fluoroethyl azide purification. Applied Radiation and Isotopes. 94:72-76. 2014
- Lau LFWilliams DSLee STScott AMChristophi CMuralidharan V. Metabolic response to preoperative chemotherapy predicts prognosis for patients undergoing surgical resection of colorectal cancer metastatic to the liver. Annals of Surgical Oncology. 21:2420-2428. 2014
- Ciprotti MChong GGan HKChan AMurone CMacGregor DLee FTJohns TGHeath JKErnst MBurgess AWScott AM. Quantitative intratumoural microdistribution and kinetics of 131I-huA33 antibody in patients with colorectal carcinoma. EJNMMI Research. 4:1-10. 2014
- Laurens EYeoh SDRigopoulos ACao DCartwright GAO'Keefe GJTochon-Danguy HJWhite JMScott AMAckermann U. Radiolabelling and evaluation of a novel sulfoxide as a PET imaging agent for tumor hypoxia. Nuclear Medicine and Biology. 41:419-425. 2014
- Alt KPaterson BMArdipradja KSchieber CBuncic GLim BPoniger SSJakoby BWang XOkeefe GJTochon-Danguy HJScott AMAckermann UPeter KDonnelly PSHagemeyer CE. Single-Chain antibody conjugated to a cage amine chelator and labeled with positron-emitting copper-64 for diagnostic imaging of activated platelets. Molecular Pharmaceutics. 11:2855-2863. 2014
- Herbertson RATebbutt NCLee FTGill SChappell BCavicchiolo TSaunder TO'Keefe GJPoon ALee STMurphy RHopkins WScott FEScott AM. Targeted chemoradiation in metastatic colorectal cancer: A phase i trial of 131i-hua33 with concurrent capecitabine. Journal of Nuclear Medicine. 55:534-539. 2014
- Vail MEMurone CTan AHii LAbebe DJanes PWLee FTBaer MPalath VBebbington CYarranton GLlerena CGaric SAbramson DCartwright GScott AMLackmann M. Targeting EphA3 inhibits cancer growth by disrupting the tumor stromal microenvironment. Cancer Research. 74:4470-4481. 2014
- Lee STJi HGreening DWSpeirs RWHRigopoulos APillay VMurone CVitali AStühler KJohns TGCorner GAMariadason JMSimpson RJScott AM. Global protein profiling reveals anti-EGFR monoclonal antibody 806-modulated proteins in A431 tumor xenografts. Growth Factors. 31:154-164. 2013
- Lawrentschuk NLee STScott AM. Current role of PET, CT, MR for invasive bladder cancer. Current Urology Reports. 14:84-89. 2013
- Chang JHWada MAnderson NJLim Joon DLee STGong SJGunawardana DHSachinidis JO'Keefe GGan HKKhoo VScott AM. Hypoxia-targeted radiotherapy dose painting for head and neck cancer using 18F-FMISO PET: A biological modeling study. Acta Oncologica. 52:1723-1729. 2013
- Burvenich IJGLee FTCartwright GAO'Keefe GJMakris DCao DGong SChueh ACMariadason JMBrechbiel MWBeckman RAFujiwara KVon Roemeling RScott AM. Molecular imaging of death receptor 5 occupancy and saturation kinetics in vivo by humanized monoclonal antibody CS-1008. Clinical Cancer Research. 19:5984-5993. 2013
- Ritchie DSNeeson PJKhot APeinert STai TTainton KChen KShin MWall DMHönemann DGambell PWesterman DAHaurat JWestwood JAScott AMKravets LDickinson MTrapani JASmyth MJDarcy PKKershaw MHPrince HM. Persistence and efficacy of second generation CAR T Cell against the LeY Antigen in acute myeloid leukemia. Molecular Therapy. 21:2122-2129. 2013
- Dao TYan SVeomett NPankov DZhou LKorontsvit TScott AWhitten JMaslak PCasey ETan TLiu HZakhaleva VCurcio MDoubrovina EO'Reilly RJLiu CScheinberg DA. Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Science Translational Medicine. 5:1-11. 2013
- Tauro BJGreening DWMathias RAJi HMathivanan SScott AMSimpson RJ. Comparison of ultracentrifugation, density gradient separation, and immunoaffinity capture methods for isolating human colon cancer cell line LIM1863-derived exosomes. Methods. 56:293-304. 2012
- Atapattu LSaha NLlerena CVail MEScott AMNikolov DBLackmann MJanes PW. Antibodies binding the ADAM10 substrate recognition domain inhibit Eph function. Journal of Cell Science. 125:6084-6093. 2012
- Scott AMWolchok JDOld LJ. Antibody therapy of cancer. Nature Reviews: Cancer. 12:278-287. 2012
- Weickhardt AJPrice TJChong GGebski VPavlakis NJohns TGAzad ASkrinos EFluck KDobrovic ASalemi RScott AMMariadason JMTebbutt NC. Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer. Journal of Clinical Oncology. 30:1505-1512. 2012
- Mcleish ARLee STByrne AJScott AM. Impact of 18F-FDG-PET in decision making for liver metastectomy of colorectal cancer. ANZ Journal of Surgery. 82:30-35. 2012
- Chang JHLim Joon DLee STGong SJAnderson NJScott AMDavis IDClouston DBolton DHamilton CSKhoo V. Intensity modulated radiation therapy dose painting for localized prostate cancer using C-choline positron emission tomography scans. International Journal of Radiation: Oncology - Biology - Physics. 83:e692-e697. 2012
- Walker FRothacker JHenderson CNice ECCatimel BZhang HHScott AMBailey MFOrchard SGAdams TELiu ZGarrett TPJClayton AHABurgess AW. Ligand binding induces a conformational change in epidermal growth factor receptor dimers. Growth Factors. 30:394-409. 2012
- Shimoni OPostma AYan YScott AMHeath JKNice ECZelikin ANCaruso F. Macromolecule functionalization of disulfide-bonded polymer hydrogel capsules and cancer cell targeting. ACS Nano. 6:1463-1472. 2012
- Haro KJScott ACScheinberg DA. Mechanisms of resistance to high and low linear energy transfer radiation in myeloid leukemia cells. Blood. 120:2087-2097. 2012
- Scott AMAllison JPWolchok JD. Monoclonal antibodies in cancer therapy. Cancer Immunity. 12. 2012
- Greenall SAGherardi ELiu ZDonoghue JFVitali AALi QMurphy RIamele LScott AMJohns TG. Non-agonistic bivalent antibodies that promote c-MET degradation and inhibit tumor growth and others specific for tumor related c-MET.. PLoS ONE. 7. 2012
- Lawrentschuk NSasges DTasevski RAbouassaly RScott AMDavis ID. Oncology health information quality on the internet: A multilingual evaluation. Annals of Surgical Oncology. 19:706-713. 2012
- Lee STLawrentschuk NScott AM. PET in prostate and bladder tumors. Seminars in Nuclear Medicine. 42:231-246. 2012
- Scott AMMitchell PLO'Keefe GSaunder THicks RJPoon ABaum CBrega NMcCarthy TJToner GC. Pharmacodynamic analysis of tumour perfusion assessed by 15O-water-PET imaging during treatment with sunitinib malate in patients with advanced malignancies. EJNMMI Research. 2. 2012
- Muralidharan VKwok MLee STLau LScott AMChristophi C. Prognostic ability of 18F-FDG PET/CT in the assessment of colorectal liver metastases. Journal of Nuclear Medicine. 53:1345-1351. 2012
- Fischer EChaitanya KWuëst TWadle AScott AMVan Den Broek MSchibli RBauer SRenner C. Radioimmunotherapy of fibroblast activation protein positive tumors by rapidly internalizing antibodies. Clinical Cancer Research. 18:6208-6218. 2012
- Laurens EYeoh SDRigopoulos ACao DCartwright GAO'Keefe GJTochon-Danguy HJWhite JMScott AMAckermann U. Radiolabelling and evaluation of novel haloethylsulfoxides as PET imaging agents for tumor hypoxia. Nuclear Medicine and Biology. 39:871-882. 2012
- Clemons NJWang DHCroagh DTikoo AFennell CMMurone CScott AMNeil Watkins DPhillips WA. Sox9 drives columnar differentiation of esophageal squamous epithelium: A possible role in the pathogenesis of Barrett's esophagus. American Journal of Physiology: Gastrointestinal and Liver Physiology. 303:G1335-G1346. 2012
- Johnston APRKamphuis MMJSuch GKScott AMNice ECHeath JKCaruso F. Targeting cancer cells: Controlling the binding and internalization of antibody-functionalized capsules. ACS Nano. 6:6667-6674. 2012
- Gan HKBurgess AWClayton AHAScott AM. Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy. Cancer Research. 72:2924-2930. 2012
- Dhomen NSMariadason JTebbutt NScott AM. Therapeutic targeting of the epidermal growth factor receptor in human cancer. Critical Reviews in Oncogenesis. 17:31-50. 2012
- Cvrljevic ANAkhavan DWu MMartinello PFurnari FBJohnston AJGuo DPike LCavenee WKScott AMMischel PSHoogenraad NJJohns TG. Activation of Src induces mitochondrial localisation of de2-7EGFR (EGFRvIII) in glioma cells: implications for glucose metabolism. Journal of Cell Science. 124:2938-2950. 2011
- Ackermann UYeoh SDSachinidis JIPoniger SSScott AMTochon-Danguy HJ. A simplified protocol for the automated production of succinimidyl 4-[ 18F]fluorobenzoate on an IBA Synthera module. Journal of Labelled Compounds and Radiopharmaceuticals. 54:671-673. 2011
- Pillay VGan HKScott AM. Antibodies in oncology. New Biotechnology. 28:518-529. 2011
- Murri-Plesko MTHulikova AOosterwijk EScott AMZortea AHarris ALRitter GOld LBauer SSwietach PRenner C. Antibody inhibiting enzymatic activity of tumour-associated carbonic anhydrase isoform IX. Behavioural Processes. 657:173-183. 2011
- Binns DSPirzkall AYu WCallahan JMileshkin LConti PScott AMMacFarlane DFine BMHicks RJ. Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging. 38:642-650. 2011
- Kozer NKelly MPOrchard SBurgess AWScott AMClayton AHA. Differential and synergistic effects of epidermal growth factor receptor antibodies on unliganded ErbB dimers and oligomers. Biochemistry. 50:3581-3590. 2011
- Feigen MLee STLawford CChurcher KZupan EScott AMHamilton C. Establishing locoregional control of malignant pleural mesothelioma using high-dose radiotherapy and 18F-FDG PET/CT scan correlation. Journal of Medical Imaging and Radiation Oncology. 55:320-332. 2011
- Ymer SIGreenall SACvrljevic ACao DXDonoghue JFChandana Epa VScott AMAdams TEJohns TG. Glioma specific extracellular missense mutations in the first cysteine rich region of epidermal growth factor receptor (EGFR) initiate ligand independent activation. Cancers. 3:2032-2049. 2011
- Chang JHJoon DLLee STGong SJScott AMDavis IDClouston DBolton DHamilton CSKhoo V. Histopathological correlation of 11C-choline PET scans for target volume definition in radical prostate radiotherapy. Radiotherapy and Oncology. 99:187-192. 2011
- Ma YKowolik CMSwiderski PMKortylewski MYu HHorne DAJove RCaballero OLSimpson AJGLee FTPillay VScott AM. Humanized Lewis-Y specific antibody based delivery of STAT3 siRNA. ACS Chemical Biology. 6:962-970. 2011
- Lawrentschuk NLee FTJones GRigopoulos AMountain AO'Keefe GPapenfuss ATBolton DMDavis IDScott AM. Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and 124I-cG250 PET/CT. Urologic Oncology: seminars and original investigations. 29:411-420. 2011
- Barnett SBaste JMMurugappan KTog CBerlangieri SScott ASeevanayagam SKnight S. Long-term survival of 42 patients with resected N2 non-small-cell lung cancer: The impact of 2-18F-fluoro-2-deoxy-d-glucose positron emission tomogram mediastinal staging. European Journal of Cardio-Thoracic Surgery. 39:96-101. 2011
- Beckman RAVon Roemeling RScott AM. Monoclonal antibody dose determination and biodistribution into solid tumors. Therapeutic Delivery. 2:333-344. 2011
- Burton KJChappell BMLee STBerlangieri SUThomas DLScott AMRowe CC. Multi-modality confirmation of splenosis. Gamma Gazette. 1:32-33. 2011
- Ramsland PAFarrugia WBradford TMSardjono CTEsparon STrist HMPowell MSTan PSCendron ACWines BDScott AMHogarth PM. Structural basis for FcγRIIa recognition of human IgG and formation of inflammatory signaling complexes. Journal of Immunology. 187:3208-3217. 2011
- Ackermann USigmund DYeoh SDRigopoulos AO'Keefe GCartwright GWhite JScott AMTochon-Danguy HJ. Synthesis of 2-[(4-[ 18F]Fluorobenzoyloxy)methyl]-1,4- naphthalenedione from 2-hydroxymethyl 1,4-naphthoquinone and 4-[ 18F]fluorobenzoic acid using dicyclohexyl carbodiimide. Journal of Labelled Compounds and Radiopharmaceuticals. 54:788-794. 2011
- Ackermann UO'Keefe GLee STRigopoulos ACartwright GSachinidis JIScott AMTochon-Danguy HJ. Synthesis of a [18F]fluoroethyltriazolylthymidine radiotracer from [18F]2-fluoroethyl azide and 5-ethynyl-2′-deoxyuridine. Journal of Labelled Compounds and Radiopharmaceuticals. 54:260-266. 2011
- Kamphuis MMJJohnston APRSuch GKDam HHEvans RAScott AMNice ECHeath JKCaruso F. Targeting of Cancer Cells Using Click-Functionalized Polymer Capsules. Journal of the American Chemical Society. 132:15881-15883. 2010
- Hricak HChoi BIScott AMSugimura KMuellner Avon Schulthess GKReiser MFGraham MMDunnick NRLarson SM. Global Trends in Hybrid Imaging. Radiology. 257:498-506. 2010
- Johns TGMcKay MJCvrljevic ANGan HKTaylor CXu HSmyth FEScott AM. MAb 806 Enhances the Efficacy of Ionizing Radiation in Glioma Xenografts Expressing the de2-7 Epidermal Growth Factor Receptor. International Journal of Radiation: Oncology - Biology - Physics. 78:572-578. 2010
- Barber TWTing Lee SLim EKiat Lim HScott AM. Benign Ectopic Multinodular Thyroid Tissue in the Submandibular Region With a Coexistent Normotopic Multinodular Thyroid Gland Harboring Papillary Thyroid Cancer. Clinical Nuclear Medicine. 35:618-619. 2010
- Azad AChionh FScott AMLee STBerlangieri SUWhite SMitchell PL. High Impact of 18F-FDG-PET on Management and Prognostic Stratification of Newly Diagnosed Small Cell Lung Cancer. Molecular Imaging and Biology. 12:443-451. 2010
- Olver JSO'Keefe GJones GRBurrows GDTochon-Danguy HJAckermann UScott AMNorman TR. Dopamine D1 receptor binding in the anterior cingulate cortex of patients with obsessive–compulsive disorder. Psychiatry Research: Neuroimaging. 183:85-88. 2010
- Lee FTO'Keefe GJGan HKMountain AJJones GRSaunder THSagona JRigopoulos ASmyth FEJohns TGGovindan SVGoldenberg DMOld LJScott AM. Immuno-PET Quantitation of de2-7 Epidermal Growth Factor Receptor Expression in Glioma Using 124I-IMP-R4-Labeled Antibody ch806. Journal of Nuclear Medicine. 51:967-972. 2010
- Lawrentschuk NScott AMDavis ID. Potential of imaging biomarkers for characterization of renal masses. Expert Review of Anticancer Therapy: an essential contribution to decision making in cancer care. 10:781-786. 2010
- Lawrentschuk NDavis IDBolton DMScott AM. Functional imaging of renal cell carcinoma. Nature Reviews: Urology. 7:258-266. 2010
- Peinert SPrince HMGuru PMKershaw MHSmyth MJTrapani JAGambell PHarrison SScott AMSmyth FEDarcy PKTainton KNeeson PRitchie DSHönemann D. Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen. Gene Therapy (Basingstoke). 17:678-686. 2010
- Vervoort LBurvenich IStaelens SDumolyn CWaegemans EVan Steenkiste MBaird SKScott AMDe Vos F. Preclinical Evaluation of Monoclonal Antibody 14C5 for Targeting Pancreatic Cancer. Cancer Biotherapy and Radiopharmaceuticals. 25:193-205. 2010
- Thiel MWolfs M-JBauer SWenning ASBurckhart TSchwarz ECScott AMRenner CHoth M. Efficiency of T-cell costimulation by CD80 and CD86 cross-linking correlates with calcium entry. Immunology. 129:28-40. 2010
- Farrugia WScott AMRamsland PA. A Possible Role for Metallic Ions in the Carbohydrate Cluster Recognition Displayed by a Lewis Y Specific Antibody. PLoS ONE. 4:e7777-e7777. 2009
- Herbertson RATebbutt NCLee F-TMacFarlane DJChappell BMicallef NLee S-TSaunder THopkins WSmyth FEWyld DKBellen JSonnichsen DSBrechbiel MWMurone CScott AM. Phase I Biodistribution and Pharmacokinetic Study of Lewis Y-Targeting Immunoconjugate CMD-193 in Patients with Advanced Epithelial Cancers. Clinical Cancer Research. 15:6709-6715. 2009
- Lee STGhanem MHerbertson RABerlangieri SUByrne AJTabone KMitchell PKnight SRFeigen MScott AM. Prognostic Value of 18F-FDG PET/CT in Patients with Malignant Pleural Mesothelioma. Molecular Imaging and Biology. 11:473-479. 2009
- Gan HKLappas MCao DXCvrljevdic AScott AMJohns TG. Targeting a unique EGFR epitope with monoclonal antibody 806 activates NF-κB and initiates tumour vascular normalization. Journal of Cell and Molecular Medicine. 13:3993-4001. 2009
- Bauer SOosterwijk-Wakka JCAdrian NOosterwijk EFischer EWüest TStenner FPerani ACohen LKnuth ADivgi CJäger DScott AMRitter GOld LJRenner C. Targeted therapy of renal cell carcinoma: Synergistic activity of cG250-TNF and IFNg. International Journal of Cancer. 125:115-123. 2009
- Pillay VAllaf LWilding ALDonoghue JFCourt NWGreenall SAScott AMJohns TG. The Plasticity of Oncogene Addiction: Implications for Targeted Therapies Directed to Receptor Tyrosine Kinases. Neoplasia. 11:448-IN2. 2009
- Olver JSO'Keefe GJones GRBurrows GDTochon-Danguy HJAckermann UScott ANorman TR. Dopamine D1 receptor binding in the striatum of patients with obsessive–compulsive disorder. Journal of Affective Disorders. 114:321-326. 2009
- Gill SCosolo WHerbertson RABerlangieri SUScott AM. Medullary carcinoma of the thyroid in a patient with colon cancer and a rising carcinoembryonic antigen level. Internal Medicine Journal. 39:264-265. 2009
- Westwood JAMurray WKTrivett MHaynes NMSolomon BMileshkin LBall DMichael MBurman AMayura-Guru PTrapani JAPeinert SHönemann DMiles Prince HScott AMSmyth MJDarcy PKKershaw MH. The Lewis-Y Carbohydrate Antigen is Expressed by Many Human Tumors and Can Serve as a Target for Genetically Redirected T cells Despite the Presence of Soluble Antigen in Serum. Journal of Immunotherapy. 32:292-301. 2009
- Garrett TPJBurgess AWGan HKLuwor RBCartwright GWalker FOrchard SGClayton AHANice ECRothacker JCatimel BCavenee WKOld LJStockert ERitter GAdams TEHoyne PAWittrup DChao GCochran JRLuo CLou MHuyton TXu YFairlie WDYao SScott AMJohns TG. Antibodies specifically targeting a locally misfolded region of tumor associated EGFR. Proceedings of the National Academy of Sciences of USA. 106:5082-5087. 2009
- Herbertson RAScarsbrook AFLee STTebbutt NScott AM. Established, emerging and future roles of PET/CT in the management of colorectal cancer. Clinical Radiology. 64:225-237. 2009
- Chatterton BEHo Shon IBaldey ALenzo NPatrikeos AKelley BWong DRamshaw JEScott AM. Positron emission tomography changes management and prognostic stratification in patients with oesophageal cancer: results of a multicentre prospective study. European Journal of Nuclear Medicine and Molecular Imaging. 36:354-361. 2009
- Scott AMGunawardana DHWong JKirkwood IHicks RJHo Shon IRamshaw JERobins P. Positron emission tomography changes management, improves prognostic stratification and is superior to gallium scintigraphy in patients with low-grade lymphoma: results of a multicentre prospective study. European Journal of Nuclear Medicine and Molecular Imaging. 36:347-353. 2009
- Macfarlane DSocrates AEisenberg PLarcos GRoach PGerometta MSmart RTsui WScott AM. Imaging of deep venous thrombosis in patients using a radiolabelled anti-D-dimer Fab′ fragment (99mTc-DI-DD3B6/22-80B3): results of a phase I trial. European Journal of Nuclear Medicine and Molecular Imaging. 36:250-259. 2009
- Adams TEKoziolek EJHoyne PHBentley JDLu LLovrecz GWard CWLee FTScott AMNash ADRothacker JNice ECBurgess AWJohns TGAdams TEKoziolek EJHoyne PHBentley JDLu LLovrecz GWard CWLee FTScott AMNash ADRothacker JNice ECBurgess AWJohns TG. A truncated soluble epidermal growth factor receptor-Fc fusion ligand trap displays anti-tumour activity in vivo. Growth Factors. 27:141-154. 2009
- Kelly MPLee STLee F-TSmyth FEDavis IDBrechbiel MWScott AM. Therapeutic efficacy of 177 Lu-CHX-A″-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy. The Prostate. 69:92-104. 2009
- He JO'Keefe GJGong SJJones GSaunder TScott AMGeso M. A Novel Method for Respiratory Motion Gated With Geometric Sensitivity of the Scanner in 3D PET. IEEE Transactions on Nuclear Science. 55:2557-2565. 2008
- Scott AMGunawardana DHBartholomeusz DRamshaw JELin P. PET Changes Management and Improves Prognostic Stratification in Patients with Head and Neck Cancer: Results of a Multicenter Prospective Study. Journal of Nuclear Medicine. 49:1593-1600. 2008
- Scott AMGunawardana DHKelley BStuckey JGByrne AJRamshaw JEFulham MJ. PET Changes Management and Improves Prognostic Stratification in Patients with Recurrent Colorectal Cancer: Results of a Multicenter Prospective Study. Journal of Nuclear Medicine. 49:1451-1457. 2008
- Kelly MPLee F-TTahtis KPower BESmyth FEBrechbiel MWHudson PJScott AM. Tumor Targeting by a Multivalent Single-Chain Fv (scFv) Anti-Lewis Y Antibody Construct. Cancer Biotherapy and Radiopharmaceuticals. 23:411-424. 2008
- Westwood JAMurray WKTrivett MShin ANeeson PMacGregor DPHaynes NMTrapani JAMayura-Guru PFox SPeinert SHonemann DPrince HMRitchie DScott AMSmyth FESmyth MJDarcy PKKershaw MH. Absence of retroviral vector-mediated transformation of gene-modified T cells after long-term engraftment in mice. Gene Therapy (Basingstoke). 15:1056-1066. 2008
- Nguyen BTJoon DLKhoo VQuong GChao MWada MJoon MLSee AFeigen MRykers KKai CZupan EScott A. Assessing the impact of FDG-PET in the management of anal cancer. Radiotherapy and Oncology. 87:376-382. 2008
- Kageyama SKitano SHirayama MNagata YImai HShiraishi TAkiyoshi KScott AMMurphy RHoffman EWOld LJKatayama NShiku H. Humoral immune responses in patients vaccinated with 1–146 HER2 protein complexed with cholesteryl pullulan nanogel. Cancer Science. 99:601-607. 2008
- Lee STTan TPoon AMTToh HBGill SBerlangieri SUKraft EByrne AJPathmaraj KO’Keefe GJTebbutt NScott AM. Role of Low-dose, Noncontrast Computed Tomography from Integrated Positron Emission Tomography/Computed Tomography in Evaluating Incidental 2-Deoxy-2-[F-18]fluoro-d-glucose-avid Colon Lesions. Molecular Imaging and Biology. 10:48-53. 2008
- He JO'Keefe GJJones GSaunder TGong SJGeso MScott AM. Evaluation of geometrical sensitivity for respiratory motion gating by GATE and NCAT simulation.. Annual International Conference of the IEEE Engineering in Medicine and Biology - Proceedings. 2007:4165-4168. 2007
- Perera RMZoncu RJohns TGPypaert MLee F-TMellman IOld LJToomre DKScott AM. Internalization, Intracellular Trafficking, Biodistribution of Monoclonal Antibody 806: A Novel Anti-Epidermal Growth Factor Receptor Antibody. Neoplasia. 9:1099-1110. 2007
- Lee STScott AM. Hypoxia Positron Emission Tomography Imaging With 18F-Fluoromisonidazole. Seminars in Nuclear Medicine. 37:451-461. 2007
- Scott AMLee FTTebbutt NHerbertson RGill SSLiu ZSkrinos EMurone CSaunder THChappell BPapenfuss ATPoon AMTHopkins WSmyth FEMacGregor DCher LMJungbluth AARitter GBrechbiel MWMurphy RBurgess AWHoffman EWJohns TGOld LJ. Correction for Scott et al., A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proceedings of the National Academy of Sciences of USA. 104:15965-15965. 2007
- Krug LMMilton DTJungbluth AAChen L-CQuaia EPandit-Taskar NNagel AJones JKris MGFinn RSmith-Jones PScott AMOld LDivgi C. Targeting Lewis Y (Ley) in Small Cell Lung Cancer with a Humanized Monoclonal Antibody, hu3S193: A Pilot Trial Testing Two Dose Levels. Journal of Thoracic Oncology. 2:947-952. 2007
- Davis IDWiseman GALee FTGansen DNHopkins WPapenfuss ATLiu ZMoynihan TJCroghan GAAdjei AAHoffman EWIngle JNOld LJScott AM. A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma.. Cancer Immunity. 7:13. 2007
- Davis IDLiu ZSaunders WLee FTSpirkoska VHopkins WSmyth FEChong GPapenfuss ATChappell BPoon ASaunder THHoffman EWOld LJScott AM. A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma.. Cancer Immunity. 7:14. 2007
- Cortez CTomaskovic-Crook EJohnston APRScott AMNice ECHeath JKCaruso F. Influence of Size, Surface, Cell Line, and Kinetic Properties on the Specific Binding of A33 Antigen-Targeted Multilayered Particles and Capsules to Colorectal Cancer Cells. ACS Nano. 1:93-102. 2007
- Davis IDWiseman GALee FTGansen DNHopkins WPapenfuss ATLiu ZMoynihan TJCroghan GAAdjei AAHoffman EWIngle JNOld LJScott AM. A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma. Cancer Immunity. 7. 2007
- Davis IDLiu ZSaunders WLee FTSpirkoska VHopkins WSmyth FEChong GPapenfuss ATChappell BPoon ASaunder THHoffman EWOld LJScott AM. A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma. Cancer Immunity. 7. 2007
- Scott AMTebbutt NLee F-TCavicchiolo TLiu ZGill SPoon AMTHopkins WSmyth FEMurone CMacGregor DPapenfuss ATChappell BSaunder THBrechbiel MWDavis IDMurphy RChong GHoffman EWOld LJ. A Phase I Biodistribution and Pharmacokinetic Trial of Humanized Monoclonal Antibody Hu3s193 in Patients with Advanced Epithelial Cancers that Express the Lewis-Y Antigen. Clinical Cancer Research. 13:3286-3292. 2007
- He JO'Keefe GJones GSaunder TGong SScott AGeso M. SU-FF-I-106: Simulation of Respiratory Motion Gating Using GATE and NCAT. Medical Physics. 34:2362-2362. 2007
- Lee STBerlangieri SUPoon AMTMitchell PPathmaraj KTabone KByrne AJO?Keefe GJKnight SRClarke CPScott AM. Prevalence of occult metastatic disease in patients undergoing 18 F-FDG PET for primary diagnosis or staging of lung carcinoma and solitary pulmonary nodules. Internal Medicine Journal. 0:070521010100001-???. 2007
- Cebon JFindlay MHargreaves CStockler MThompson PBoyer MRoberts SPoon AScott AMKalff VGaras GDowling ACrawford DRing JBasser RStrickland AMacdonald GGreen MNowak ADickman BDhillon HGebski V. Somatostatin receptor expression, tumour response and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide. British Journal of Cancer. 96:1154-1154. 2007
- Herbertson RALee STTebbutt NScott AM. The expanding role of PET technology in the management of patients with colorectal cancer. Annals of Oncology. 18:1774-1781. 2007
- Johns TGPerera RMVernes SCVitali AACao DXCavenee WKScott AMFurnari FB. The Efficacy of Epidermal Growth Factor Receptor-Specific Antibodies against Glioma Xenografts Is Influenced by Receptor Levels, Activation Status, and Heterodimerization. Clinical Cancer Research. 13:1911-1925. 2007
- Scott AMLee F-TTebbutt NHerbertson RGill SSLiu ZSkrinos EMurone CSaunder THChappell BPapenfuss ATPoon AMTHopkins WSmyth FEMacGregor DCher LMJungbluth AARitter GBrechbiel MWMurphy RBurgess AWHoffman EWJohns TGOld LJ. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proceedings of the National Academy of Sciences of USA. 104:4071-4076. 2007
- Gan HKWalker FBurgess AWRigopoulos AScott AMJohns TG. The Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor AG1478 Increases the Formation of Inactive Untethered EGFR Dimers. Journal of Biological Chemistry. 282:2840-2850. 2007
- Yücel MBrewer WJHarrison BJFornito AO'Keefe GJOlver JScott AMEgan GFVelakoulis DMcGorry PDPantelis C. Anterior cingulate activation in antipsychotic-naïve first-episode schizophrenia. Acta Psychiatrica Scandinavica. 115:155-158. 2007
- Lawrentschuk NDavis IDBolton DMScott AM. Diagnostic and therapeutic use of radioisotopes for bony disease in prostate cancer: Current practice. International Journal of Urology. 14:89-95. 2007
- Lawrentschuk NBolton DDavis IScott A. Renal Cell Cancer and Positron Emission Tomography- an Evolving Diagnostic and Therapeutic Relationship. Current Medical Imaging Reviews. 3:17-26. 2007
- Li DJi HZaghlul SMcNamara KLiang M-CShimamura TKubo STakahashi MChirieac LRPadera RFScott AMJungbluth AACavenee WKOld LJDemetri GDWong K-K. Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant–dependent lung carcinomas. Journal of Clinical Investigation. 117:346-352. 2007
- Kitano SKageyama SNagata YMiyahara YHiasa ANaota HOkumura SImai HShiraishi TMasuya MNishikawa MSunamoto JAkiyoshi KKanematsu TScott AMMurphy RHoffman EWOld LJShiku H. HER2-Specific T-Cell Immune Responses in Patients Vaccinated with Truncated HER2 Protein Complexed with Nanogels of Cholesteryl Pullulan. Clinical Cancer Research. 12:7397-7405. 2006
- Lawrentschuk NPoon AMTScott AM. Fluorine-18 Fluorothymidine: A New Positron Emission Radioisotope for Renal Tumors. Clinical Nuclear Medicine. 31:788-789. 2006
- Cherk MHFoo SSPoon AMTKnight SRMurone CPapenfuss ATSachinidis JISaunder THCO'Keefe GJScott AM. Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by18F- fluoromisonidazole and18F-FDG PET. Journal of Nuclear Medicine. 47:1921-1926. 2006
- Belhocine TZScott AMEven-Sapir EUrbain JLEssner R. Role of nuclear medicine in the management of cutaneous malignant melanoma. Journal of Nuclear Medicine. 47:957-967. 2006
- Sakamoto JOriuchi NMochiki EAsao TScott AMHoffman EWJungbluth AAMatsui TLee FTPapenfuss AKuwano HTakahashi TEndo KOld LJ. A phase I radioimmunolocalization trial of humanized monoclonal antibody huA33 in patients with gastric carcinoma. Cancer Science. 97:1248-1254. 2006
- Falzon CLAckermann USpratt NTochon-Danguy HJWhite JHowells DScott AM. F-18 labelledN,N-bis-haloethylamino-phenylsulfoxides — a new class of compounds for the imaging of hypoxic tissue. Journal of Labelled Compounds and Radiopharmaceuticals. 49:1089-1103. 2006
- Harrison BJYücel MShaw MKyrios MMaruff PBrewer WJPurcell RVelakoulis DStrother SCScott AMNathan PJPantelis C. Evaluating brain activity in obsessive–compulsive disorder: Preliminary insights from a multivariate analysis. Psychiatry Research: Neuroimaging. 147:227-231. 2006
- Michael MThompson MHicks RJMitchell PLEllis AMilner ADDi Iulio JScott AMGurtler VHoskins JMClarke SJTebbut NCFoo KJefford MZalcberg JR. Relationship of Hepatic Functional Imaging to Irinotecan Pharmacokinetics and Genetic Parameters of Drug Elimination. Journal of Clinical Oncology. 24:4228-4235. 2006
- Cortez CTomaskovic-Crook EJohnston APRRadt BCody SHScott AMNice ECHeath JKCaruso F. Targeting and Uptake of Multilayered Particles to Colorectal Cancer Cells. Advanced Materials. 18:1998-2003. 2006
- Macfarlane DJSmart RCTsui WWGerometta MEisenberg PRScott AM. Safety, pharmacokinetic and dosimetry evaluation of the proposed thrombus imaging agent 99mTc-DI-DD-3B6/22-80B3 Fab′. European Journal of Nuclear Medicine and Molecular Imaging. 33:648-656. 2006
- LAWRENTSCHUK NDAVIS IDBOLTON DMSCOTT AM. Positron emission tomography (PET), immuno-PET and radioimmunotherapy in renal cell carcinoma: a developing diagnostic and therapeutic relationship. BJU International. 97:916-922. 2006
- LAWRENTSCHUK NDAVIS IDBOLTON DMSCOTT AM. Positron emission tomography and molecular imaging of the prostate: an update. BJU International. 97:923-931. 2006
- Ellis AGDoherty MMWalker FWeinstock JNerrie MVitali AMurphy RJohns TGScott AMLevitzki AMcLachlan GWebster LKBurgess AWNice EC. Preclinical analysis of the analinoquinazoline AG1478, a specific small molecule inhibitor of EGF receptor tyrosine kinase. Biochemical Pharmacology. 71:1422-1434. 2006
- Kelly MPLee FTSmyth FEBrechbiel MWScott AM. Enhanced efficacy of 90Y-radiolabeled anti-lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model. Journal of Nuclear Medicine. 47:716-725. 2006
- Essner RBelhocine TScott AMEven-Sapir E. Novel Imaging Techniques in Melanoma. Surgical Oncology Clinics of North America. 15:253-283. 2006
- Cher LMMurone CLawrentschuk NRamdave SPapenfuss AHannah AO'Keefe GJSachinidis JIBerlangieri SUFabinyi GScott AM. Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies. Journal of Nuclear Medicine. 47:410-418. 2006
- Ackermann UBlanc PFalzon CLIssa WWhite JTochon-Danguy HJSachinidis JIScott AM. Synthesis of 11C labelled methyl esters: transesterification of enol esters versus BF3 catalysed esterification—a comparative study. Radiation Physics and Chemistry. 75:48-52. 2006
- Lawrentschuk NRigopoulos ALee F-TDavis IDScott AMBolton DM. Xenografting Tumour beneath the Renal Capsule Using Modern Surgical Equipment. European Surgical Research: clinical and experimental surgery. 38:340-346. 2006
- Westwood JASmyth MJTeng MWLMoeller MTrapani JAScott AMSmyth FECartwright GAPower BEHonemann DPrince HMDarcy PKKershaw MH. Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. Proceedings of the National Academy of Sciences of USA. 102:19051-19056. 2005
- Rowe CO'Keefe GScott AMTochon-Danguy HT. Positron emission tomography in neuroscience. MedicaMundi. 49:9-16. 2005
- Roberts FOGunawardana DHPathmaraj KWallace AU PLMi TBerlangieri SUO'Keefe GJRowe CCScott AM. Radiation dose to PET technologists and strategies to lower occupational exposure. Journal of Nuclear Medicine Technology. 33:44-47. 2005
- Yuriev EFarrugia WScott AMRamsland PA. Three-dimensional structures of carbohydrate determinants of Lewis system antigens: Implications for effective antibody targeting of cancer. Immunology and Cell Biology. 83:709-717. 2005
- Hicks RJRischin DFisher RBinns DScott AMPeters LJ. Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent. European Journal of Nuclear Medicine and Molecular Imaging. 32:1384-1391. 2005
- Ollenberger GPByrne AJBerlangieri SURowe CCPathmaraj KReutens DCBerkovic SFScheffer IEScott AM. Assessment of the role of FDG PET in the diagnosis and management of children with refractory epilepsy. European Journal of Nuclear Medicine and Molecular Imaging. 32:1311-1316. 2005
- Lawrentschuk NPoon AMTFoo SSPutra LGJMurone CDavis IDBolton DMScott AM. Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomography. BJU International. 96:540-546. 2005
- Yap KKYap KSKByrne AJBerlangieri SUPoon AMitchell PKnight SRClarke PCHarris ATauro ARowe CCScott AM. Positron emission tomography with selected mediastinoscopy compared to routine mediastinoscopy offers cost and clinical outcome benefits for pre-operative staging of non-small cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging. 32:1033-1040. 2005
- Scott AGan HPerera RM. Treatment of Human Tumor Xenografts with Monoclonal Antibody 806 in Combination with a Prototypical Epidermal Growth Factor Receptor-Specific Antibody Generates Enhanced Antitumor Activity. Clinical Cancer Research. 11:6390-6399. 2005
- Vearing CLee F-TWimmer-Kleikamp SSpirkoska VTo CStylianou CSpanevello MBrechbiel MBoyd AWScott AMLackmann M. Concurrent Binding of Anti-EphA3 Antibody and Ephrin-A5 Amplifies EphA3 Signaling and Downstream Responses: Potential as EphA3-Specific Tumor-Targeting Reagents. Cancer Research. 65:6745-6754. 2005
- Scott AM. Radioimmunotherapy of Prostate Cancer: Does Tumor Size Matter?. Journal of Clinical Oncology. 23:4567-4569. 2005
- Davis IDChen WJackson HParente PShackleton MHopkins WChen QDimopoulos NLuke TMurphy RScott AMMaraskovsky EMcArthur GMacGregor DSturrock STai TYGreen SCuthbertson AMaher DMiloradovic LMitchell SVRitter GJungbluth AAChen YTGnjatic SHoffman EWOld LJCebon JS. errata for Davis et al., Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans, PNAS 2004 101:10697-10702. Proceedings of the National Academy of Sciences of USA. 102:9734-9734. 2005
- Rigopoulos ALee FTCebon JScott AM. A Phase I Trial of Humanized Monoclonal Antibody A33 in Patients with Colorectal Carcinoma: Biodistribution, Pharmacokinetics, and Quantitative Tumor Uptake. Clinical Cancer Research. 11:4810-4817. 2005
- Harris MTBerlangieri SUCebon JSDavis IDScott AM. Impact of 2-Deoxy-2[F-18]Fluoro-d-Glucose Positron Emission Tomography on the Management of Patients with Advanced Melanoma. Molecular Imaging and Biology. 7:304-308. 2005
- Scott ALee FTCebon JTebbutt NChong G. Phase I Trial of 131I-huA33 in Patients with Advanced Colorectal Carcinoma. Clinical Cancer Research. 11:4818-4826. 2005
- Murphy RGreen SRitter GCohen LRyan DWoods WRubira MCebon JDavis IDSjolander AKypridis AKalnins HMcNamara MMoloney MBAckland JCartwright GRood JDumsday GHealey KMaher DMaraskovsky EChen YHoffman EWOld LJScott AM. Recombinant NY‐ESO‐1 Cancer Antigen: Production and Purification under cGMP Conditions. Preparative Biochemistry and Biotechnology. 35:119-134. 2005
- Ackermann UTochon-Danguy HJNerrie MNice ECSachinidis JIScott AM. Synthesis, 11C labeling and biological properties of derivatives of the tyrphostin AG957. Nuclear Medicine and Biology. 32:323-328. 2005
- Johns TGMellman ICartwright GARitter GOld LJBurgess AWScott AM. The antitumor monoclonal antibody 806 recognizes a high-mannose form of the EGF receptor that reaches the cell surface when cells over-express the receptor. The FASEB Journal. 19:780-782. 2005
- Panousis CRayzman VMJohns TGRenner CLiu ZCartwright GLee F-TWang DGan HCao DKypridis ASmyth FEBrechbiel MWBurgess AWOld LJScott AM. Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR. British Journal of Cancer. 92:1069-1077. 2005
- Putra LJLawrentschuk NBallok ZHannah APoon ATauro ADavis IDHicks RJBolton DMScott AM. Erratum. Urology. 65:632-632. 2005
- Scott AMLiu ZMurone CJohns TGMacGregor DSmyth FELee FTCebon JDavis IDHopkins WMountain AJRigopoulos AHanai NOld LJ. Immunological effects of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma. Cancer Immunity. 5. 2005
- Johns Putra LLawrentschuk NBallok ZHannah APoon ATauro ADavis IDHicks RJBolton DMScott AM. 18F-fluorodeoxyglucose positron emission tomography in evaluation of germ cell tumor after chemotherapy. Urology. 64:1202-1207. 2004
- FOO SABBOTT DLAWRENTSCHUK NSCOTT A. Functional imaging of intratumoral hypoxia. Molecular Imaging and Biology. 6:291-305. 2004
- Issa WTochon-Danguy HJLambert JSachinidis JIAckermann ULiu ZScott AM. Synthesis and evaluation of a thymidine analog for positron emission tomography study of tumor DNA proliferation in vivo. Nuclear Medicine and Biology. 31:839-849. 2004
- Luwor RBZhu H-JWalker FVitali AAPerera RMBurgess AWScott AMJohns TG. The tumor-specific de2–7 epidermal growth factor receptor (EGFR) promotes cells survival and heterodimerizes with the wild-type EGFR. Oncogene. 23:6095-6104. 2004
- Davis IDChen WJackson HParente PShackleton MHopkins WChen QDimopoulos NLuke TMurphy RScott AMMaraskovsky EMcArthur GMacGregor DSturrock STai TYGreen SCuthbertson AMaher DMiloradovic LMitchell SVRitter GJungbluth AAChen Y-TGnjatic SHoffman EWOld LJCebon JS. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans. Proceedings of the National Academy of Sciences of USA. 101:10697-10702. 2004
- Johns TGAdams TECochran JRHall NEHoyne PAOlsen MJKim Y-SRothacker JNice ECWalker FRitter GJungbluth AAOld LJWard CWBurgess AWWittrup KDScott AM. Identification of the Epitope for the Epidermal Growth Factor Receptor-specific Monoclonal Antibody 806 Reveals That It Preferentially Recognizes an Untethered Form of the Receptor. Journal of Biological Chemistry. 279:30375-30384. 2004
- Ackermann UTochon-Danguy HJScott AM. BF3 etherate catalysed formation of[11C]methyl esters: a novel radiolabelling technique. Journal of Labelled Compounds and Radiopharmaceuticals. 47:523-530. 2004
- Foo SSMitchell PLBerlangieri SUSmith CLScott AM. Positron emission tomography scanning in the assessment of patients with lymphoma. Internal Medicine Journal. 34:388-397. 2004
- Ramsland PAFarrugia WBradford TMMark Hogarth PScott AM. Structural Convergence of Antibody Binding of Carbohydrate Determinants in Lewis Y Tumor Antigens. Journal of Molecular Biology. 340:809-818. 2004
- Foo SSRamdave SBerlangieri SUScott AM. Detection of occult bone metastases of lung cancer with Fluorine-18 fluorodeoxyglucose positron emission tomography. Journal of Medical Imaging and Radiation Oncology. 48:214-216. 2004
- Walker FOrchard SGJorissen RNHall NEZhang H-HHoyne PAAdams TEJohns TGWard CGarrett TPJZhu H-JNerrie MScott AMNice ECBurgess AW. CR1/CR2 Interactions Modulate the Functions of the Cell Surface Epidermal Growth Factor Receptor. Journal of Biological Chemistry. 279:22387-22398. 2004
- Bauer SAdrian NWilliamson BPanousis CFadle NSmerd JFettah IScott AMPfreundschuh MRenner C. Targeted Bioactivity of Membrane-Anchored TNF by an Antibody-Derived TNF Fusion Protein. Journal of Immunology. 172:3930-3939. 2004
- Kloft CGraefe E-UTanswell PScott AMHofheinz RAmelsberg AKarlsson MO. Population Pharmacokinetics of Sibrotuzumab, A Novel Therapeutic Monoclonal Antibody, in Cancer Patients. Investigational New Drugs. 22:39-52. 2004
- Johns TGLuwor RBMurone CWalker FWeinstock JVitali AAPerera RMJungbluth AAStockert EOld LJNice ECBurgess AWScott AM. Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478. Proceedings of the National Academy of Sciences of USA. 100:15871-15876. 2003
- Tahtis KLee FTWheatley JMGarin-Chesa PPark JESmyth FEObata YStockert EHall CMOld LJRettig WJScott AM. Expression and targeting of human fibroblast activation protein in a human skin/severe combined immunodeficient mouse breast cancer xenograft model. Molecular Cancer Therapeutics. 2:729-737. 2003
- Liu ZPanousis CSmyth FEMurphy RWirth VCartwright GJohns TGScott AM. Generation of Anti-Idiotype Antibodies for Application in Clinical Immunotherapy Laboratory Analyses. Hybridoma: a journal of molecular immunology and experimental and clinical immunotherapy. 22:219-228. 2003
- Lee FTScott AM. Immuno-PET for tumor targeting. Journal of Nuclear Medicine. 44:1282-1283. 2003
- Mitchell PLee FTHall CRigopoulos ASmyth FEHekman AMVan Schijndel GMPowles RBrechbiel MWScott AM. Targeting primary human Ph+B-cell precursor leukemia-engrafted SCID mice using radiolabeled anti-CD19 monoclonal antibodies. Journal of Nuclear Medicine. 44:1105-1112. 2003
- Scott AMWiseman GWelt SAdjei ALee FTHopkins WDivgi CRHanson LHMitchell PGansen DNLarson SMIngle JNHoffman EWTanswell PRitter GCohen LSBette PArvay LAmelsberg AVlock DRettig WJOld LJ. A phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clinical Cancer Research. 9:1639-1647. 2003
- Scott ALiu ZPower BE. Noncovalent scFv multimers of tumor-targeting anti-Lewisy hu3S193 humanized antibody. Protein Science. 12:734-747. 2003
- Jungbluth AAStockert ESu Huang HJCollins VPCoplan KIversen KKolb DJohns TJScott AMGullick WJRitter GCohen LScanlan MJCavenee WKOld LJ. Erratum: A monoclonal antibody recognizing human cancers with amplifications/overexpression of the human epidermal growth factor receptor (Proceedings of the National Academy of Sciences of the United States of America (January 21, 2003) 100:2 (639-644)). Proceedings of the National Academy of Sciences of USA. 100:2163. 2003
- Froomes PRSachinidis JGhabrial HTochon-Danguy HScott AChing MSMorgan DJAngus PW. A novel method for determining hepatic sinusoidal oxygen permeability in the isolated perfused rat liver using [15O]O2. Nuclear Medicine and Biology. 30:93-100. 2003
- Jungbluth AAStockert EHuang HJSCollins VPCoplan KIversen KKolb DJohns TJScott AMGullick WJRitter GCohen LScanlan MJCavanee WKOld LJ. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proceedings of the National Academy of Sciences of USA. 100:639-644. 2003
- Liu ZLee FTHanai NSmyth FEBurgess AWOld LJScott AM. Cytokine enhancement of in vitro antibody-dependent cellular cytotoxicitymediated by chimeric anti-GD3 monoclonal antibody KM871. Cancer Immunity. 5:1-14. 2002
- Scott ACasse R. Positron Emission Tomography and Epilepsy. Molecular Imaging and Biology. 4:338-351. 2002
- Hannah AScott AMTochon-Danguy HChan JGAkhurst TBerlangieri SPrice DSmith GJSchelleman TMcKay WJSizeland A. Evaluation of 18F-Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography With Histopathologic Correlation in the Initial Staging of Head and Neck Cancer. Annals of Surgery. 236:208-217. 2002
- Markus RDonnan GAKazui SRead SHirano TScott AMO'Keefe GJTochon-Danguy HJSachinidis JIReutens DC. Statistical Parametric Mapping of Hypoxic Tissue Identified by [18F]Fluoromisonidazole and Positron Emission Tomography Following Acute Ischemic Stroke. Neuroimage. 16:425-433. 2002
- Scott ALee FTLiu ZLiu, Fiona E. Smyth, Christoph Renn Z. Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity. Cancer Immunology Immunotherapy. 51:171-177. 2002
- Johns TGStockert ERitter GJungbluth AAHuang H-JSCavenee WKSmyth FEHall CMWatson NNice ECGullick WJOld LJBurgess AWScott AM. Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene. International Journal of Cancer. 98:398-408. 2002
- Ackermann UTochon-Danguy HJYoung KSachinidis JIGordon Chan JScott AM. 11C labelling of AG957?a potential tyrphostin radiotracer for PET. Journal of Labelled Compounds and Radiopharmaceuticals. 45:157-165. 2002
- Tochon-Danguy HJSachinidis JIChan FGordon Chan JHall CCher LStylli SHill JKaye AScott AM. Imaging and quantitation of the hypoxic cell fraction of viable tumor in an animal model of intracerebral high grade glioma using [ 18 F]fluoromisonidazole (FMISO). Nuclear Medicine and Biology. 29:191-197. 2002
- Liu ZLee FTHanai NSmyth FEBurgess AWOld LJScott AM. Cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity mediated by chimeric anti-GD3 monoclonal antibody KM871.. Cancer Immunity. 2:13. 2002
- Rayzman VMScott AM. Monoclonal antibodies for cancer therapy. Cancer Forum. 26:104-108. 2002
- Scott ABrown IBoots RBowman RMcEvoy DMorrison S. Haemoptysis in the adult under 40 - a clinico-pathological review. Respirology. 6. 2001
- Gallicchio MAKneen MHall CScott AMBach LA. Overexpression of insulin-like growth factor binding protein-6 inhibits rhabdomyosarcoma growthin vivo. International Journal of Cancer. 94:645-651. 2001
- Scott AMLee F-THopkins WCebon JSWheatley JMLiu ZSmyth FEMurone CSturrock SMacGregor DHanai NInoue KYamasaki MBrechbiel MWDavis IDMurphy RHannah ALim-Joon MChan TChong GRitter GHoffman EWBurgess AWOld LJ. Specific Targeting, Biodistribution, and Lack of Immunogenicity of Chimeric Anti-GD3 Monoclonal Antibody KM871 in Patients With Metastatic Melanoma: Results of a Phase I Trial. Journal of Clinical Oncology. 19:3976-3987. 2001
- Barendswaard ECHumm JLO'Donoghue JASgouros GFinn RDScott AMLarson SMWelt S. Relative therapeutic efficacy of 125I- and 131I-labeled monoclonal antibody A33 in a human colon cancer xenograft. Journal of Nuclear Medicine. 42:1251-1256. 2001
- Mishima KJohns TGLuwor RBScott AMStockert EJungbluth AAJi XDSuvarna PVoland JROld LJSu Huang HJCavenee WK. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Research. 61:5349-5354. 2001
- Luwor RBJohns TGMurone CSu Huang HJCavenee WKRitter GOld LJBurgess AWScott AM. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. Cancer Research. 61:5355-5361. 2001
- Power BECaine JMBurns JEShapira DRHattarki MKTahtis KLee F-TSmyth FEScott AMKortt AAHudson PJ. Construction, expression and characterisation of a single-chain diabody derived from a humanised anti-Lewis Y cancer targeting antibody using a heat-inducible bacterial secretion vector. Cancer Immunology Immunotherapy. 50:241-250. 2001
-
Lee FTRigopoulos AHall CClarke KCody SHSmyth FELiu ZBrechbiel MWHanai NNice ECCatimel BBurgess AWWelt SRitter GOld LJScott AM. Specific localization, gamma camera imaging, and intracellular trafficking of radiolabelled chimeric anti-G
D3 ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts. Cancer Research. 61:4474-4482. 2001 - Lee FTHall CRigopoulos AZweit JPathmaraj KO'Keefe GJSmyth FEWelt SOld LJScott AM. Immuno-PET of human colon xenograft-bearing BALB/c nude mice using 124I-CDR-grafted humanized A33 monoclonal antibody. Journal of Nuclear Medicine. 42:764-769. 2001
- Renner CStehle ILee FTHall CCatimel BNice ECMountain ARigopoulos ABrechbiel MWPfreundschuh MScott AM. Targeting properties of an anti-CD16/anti-CD30 bispecific antibody in an in vivo system. Cancer Immunology Immunotherapy. 50:102-108. 2001
- Ramdave SThomas GWBerlangieri SUBolton DMHenri-Tochon-Danguy IDMacgregor DScott AMMacgregor D. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. Journal of Urology. 166:825-830. 2001
- Scott AM. Current status of positron emission tomography in oncology. Internal Medicine Journal. 31:27-36. 2001
- Tanswell PGarin-Chesa PRettig WJWelt SDivgi CRCasper ESFinn RDLarson SMOld LJScott AM. Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients. British Journal of Clinical Pharmacology. 51:177-180. 2001
-
Tahtis KLee FTSmyth FEPower BERenner CBrechbiel MWOld LJHudson PJScott AM. Biodistribution properties of 111indium-labeled C-functionalized trans-cyclohexyl diethylenetriaminepentaacetic acid humanized 3S193 diabody and F(ab′)
2 constructs in a breast carcinoma xenograft model. Clinical Cancer Research. 7:1061-1072. 2001 - Scott A. Overview. Cancer Forum. 24:210. 2000
- Berlangieri SScott A. PET in clinical oncology. Cancer Forum. 24:219-222. 2000
- Clarke KLee FTBrechbiel MWSmyth FEOld LJScott AM. Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: Enhanced activity when combined with taxol chemotherapy. Clinical Cancer Research. 6:3621-3628. 2000
- Clarke KLee FTBrechbiel MWSmyth FEOld LJScott AM. In vivo biodistribution of a humanized anti-Lewis Y monoclonal antibody (hu3s193) in MCF-7 xenografted BALB/c nude mice. Cancer Research. 60:4804-4811. 2000
- Read SJHirano TAbbott DFMarkus RSachinidis JITochon-Danguy HJChan JGEgan GFScott AMBladin CFMcKay WJDonnan GA. The fate of hypoxic tissue on 18F-fluoromisonidazole positron emission tomography after ischemic stroke. Annals of Neurology. 48:228-235. 2000
- Berlangieri SUScott AM. Metabolic Staging of Lung Cancer. New England Journal of Medicine. 343:290-292. 2000
- Scott AMGeleick DRubira MClarke KNice ECSmyth FEStockert ERichards ECCarr FJHarris WJArmour KLRood JKypridis AKronina VMurphy RLee FTLiu ZKitamura KRitter GLaughton KHoffman EBurgess AWOld LJ. Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors. Cancer Research. 60:3254-3261. 2000
- Achen MGRoufail SDomagala TCatimel BNice ECGeleick DMMurphy RScott AMCaesar CMakinen TAlitalo KStacker SA. Monoclonal antibodies to vascular endothelial growth factor-D block its interactions with both VEGF receptor-2 and VEGF receptor-3. The Federation of European Biochemical Societies (FEBS) Journal. 267:2505-2515. 2000
- Scott ABennett EJ. Psychological and sex features of delayed gut transit in functional gastrointestinal disorders. Gut. 46:83-87. 2000
- Thomas DLRowe CChan JGYoung KBerlangieri SNewton MCasse RScott AM. Stabilised vs standard 99 m Tc HMPAO for the localisation of epileptic foci using ictal injection - A comparison. Australian and New Zealand Nuclear Medicine. 31:96-99. 2000
- Hirano TRead SJAbbott DFSachinidis JITochon-Danguy HJEgan GFBladin CFScott AMMcKay WJDonnan GA. No evidence of hypoxic tissue on 18F-fluoromisonidazole PET after intracerebral hemorrhage. Neurology. 53:2179-2179. 1999
- Tochon-Danguy HJSachinidis JIEgan GFChan JGBerlangieri SUMcKay WJScott AM. Positron emission tomography: Radioisotope and radiopharmaceutical production. Australasian Physical and Engineering Sciences in Medicine. 22:136-144. 1999
- Houlihan CJenkins MOsicka TScott AParkin DJerums G. A comparison of the plasma disappearance of iohexol and 99m Tc-DTPA for the measurement of glomerular filtration rate (GFR) in diabetes. Australian and New Zealand Journal of Medicine. 29:693-700. 1999
- POINTON OSCOTT AMBERLANGIERI SMcKAY WJGOLDSTEIN D. F-18 Fluorodeoxyglucose PET and Ga-67 Citrate Scintigraphy in a Case of AIDS Lymphoma and Pericarditis. Clinical Nuclear Medicine. 24:817-817. 1999
- Hanna AU PWallace ASchleyer PLee FTJones RHopkins WMacGregor DCebon JRigopoulos AThomas DMcKay WJWelt SRichards EKolbert KSSgouros GOld LBurgess AWScott AM. Phase I study of humanised antibody A33 (Hua33) in patients with colorectal carcinoma - Preliminary whole body clearance and tumour dosimetry: Short title: Dosimetric analysis of [I-131]huA33. Australian and New Zealand Nuclear Medicine. 30:52-55. 1999
- Scott AReutens D. Clinical Applications of [15O] H2O PET Activation Studies. Molecular Imaging and Biology. 2:145-152. 1999
- Read SJHirano TAbbott DFSachinidis JITochon-Danguy HJChan JGEgan GFScott AMBladin CFMcKay WJDonnan GA. Identifying hypoxic tissue after acute ischemic stroke using PET and 18F-fluoromisonidazole. Neurology. 51:1617-1621. 1998
- Divgi CRBander NHScott AMO'Donoghue JASgouros GWelt SFinn RDMorrissey FCapitelli PWilliams JMDeland DNakhre AOosterwijk EGulec SGraham MCLarson SMOld LJ. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clinical Cancer Research. 4:2729-2739. 1998
- Thomas DMMitchell PLRBerlangieri SUTochon-Danguy HKnight SClarke CPScott AM. Correction: Positron emission tomography in assessing response to neoadjuvant chemotherapy for non-small-cell lung cancer (Medical Journal of Australia (1998) 169 (227)). Medical Journal of Australia. 169:344. 1998
- Thomas DMMitchell PLRBerlangieri SUTochon-Danguy HKnight SClarke CPScott AM. Positron emission tomography in assessing response to neoadjuvant chemotherapy for non-small-cell lung cancer [1]. Medical Journal of Australia. 169:227. 1998
- Catimel BScott AMLee FTHanai NRitter GWelt SOld LJBurgess AWNice EC. Direct immobilization of gangliosides onto gold-carboxymethyldextran sensor surfaces by hydrophobic interaction: applications to antibody characterization. Glycobiology. 8:927-938. 1998
- Kiffer JDBerlangieri SUScott AMQuong GFeigen MSchumer WClarke CPKnight SRDaniel FJ. The contribution of18F-fluoro-2-deoxy-glucose positron emission tomographic imaging to radiotherapy planning in lung cancer. Lung Cancer. 19:167-177. 1998
- Barendswaard ECScott AMDivgi CRWilliams CCoplan KRiedel EYao TJGansow OAFinn RDLarson SMOld LJWelt S. Rapid and specific targeting of monoclonal antibody A33 to a colon cancer xenograft in nude mice. International Journal of Oncology. 12:45-53. 1998
- Scott AMCebon J. Clinical promise of tumour immunology. Lancet. 349:SII19-SII22. 1997
- Nicholson ICLenton KALittle DJDecorso TLee FTScott AMZola HHohmann AW. Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma. Molecular Immunology. 34:1157-1165. 1997
- Scott AMWelt S. Antibody-based immunological therapies. Current Opinion in Immunology. 9:717-722. 1997
- Cebon JMacgregor DScott ADeboer R. Immunotherapy of melanoma: Targeting defined antigens. Australasian Journal of Dermatology. 38:S66-S72. 1997
- Kolbert KSSgouros GScott AMBronstein JEMalane RAZhang JKalaigian HMcNamara SSchwartz LLarson SM. Implementation and evaluation of patient-specific three-dimensional internal dosimetry. Journal of Nuclear Medicine. 38:301-308. 1997
- Heath JKWhite SJJohnstone CNCatimel BSimpson RJMoritz RLTu G-FJi HWhitehead RHGroenen LCScott AMRitter GCohen LWelt SOld LJNice ECBurgess AW. The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily. Proceedings of the National Academy of Sciences of USA. 94:469-474. 1997
- Roach PJHansen PSScott AMCooper RAHoschl RWiseman JCBernar AEdwards AC. Comparison of optimised planar scintigraphy with SPECT thallium, exercise ECG and angiography in the detection of coronary artery disease. Australian and New Zealand Journal of Medicine. 26:806-812. 1996
- Catimel BRitter GWelt SOld LJCohen LNerrie MAWhite SJHeath JKDemediuk BDomagala TLee FTScott AMTu GFJi HMoritz RLSimpson RJBurgess AWNice EC. Purification and Characterization of a Novel Restricted Antigen Expressed by Normal and Transformed Human Colonic Epithelium. Journal of Biological Chemistry. 271:25664-25670. 1996
- Hannah AScott AMAkhurst TBerlangieri SBishop JMcKay WJ. Abnormal colonic accumulation of fluorine-18-FDG in pseudomembranous colitis. Journal of Nuclear Medicine. 37:1683-1685. 1996
- Welt SScott AMDivgi CRKemeny NEFinn RDDaghighian FGermain JSRichards ECLarson SMOld LJ. Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer.. Journal of Clinical Oncology. 14:1787-1797. 1996
- Sgouros GJureidini IMScott AMGraham MCLarson SMScheinberg DA. Bone Marrow Dosimetry: Regional Variability of Marrow-Localizing Antibody. Journal of Nuclear Medicine. 37:695-698. 1996
- Burt MScott AWilliard WCPommier RYeh SBains MSTurnbull ADFortner JGMcCormack PMGinsberg RJ. Erythromycin stimulates gastric emptying after esophagectomy with gastric replacement: A randomized clinical trial. Journal of Thoracic and Cardiovascular Surgery. 111:649-654. 1996
- Daghighian FBarendswaard EWelt SHumm JScott AWillingham MCMcGuffie EOld LJLarson SM. Enhancement of Radiation Dose to the Nucleus by Vesicular Internalization of Iodine-125-Labeled A33 Monoclonal Antibody. Journal of Nuclear Medicine. 37:1052-1057. 1996
- Abdel-Dayem HMScott AMacapinlac HLarson S. Tracer imaging in lung cancer. European Journal of Nuclear Medicine and Molecular Imaging. 22:1355-1355. 1995
- Divgi CRScott AMGulec SBroussard EKLevy NYoung CCapitelli PDaghighian FWilliams JMFinn RDKemeny NHilton SKelsen DMilenic DELora MESchlom JLarson SM. Pilot Radioimmunotherapy Trial with 131I-labeled Murine Monoclonal Antibody CC49 and Deoxyspergualin in Metastatic Colon Carcinoma. Clinical Cancer Research. 1:1503-1510. 1995
- Scott AMRosa EMehta BMDivgi CRFinn RDBiedler JLTsuruo TKalaigian HLarson SM. In vivo imaging and specific targeting of P-glycoprotein expression in multidrug resistant nude mice xenografts with [125I]MRK-16 monoclonal antibody. Nuclear Medicine and Biology. 22:497-504. 1995
- Ugur OScott AMKostakoglu LHui TMasterson MEFebo RSgouros GRosa EMehta BMFisher DRCheung N-KVLarson SM. Calculated and TLD-based absorbed dose estimates for I-131-labeled 3F8 monoclonal antibody in a human neuroblastoma xenograft nude mouse model. Nuclear Medicine and Biology. 22:87-93. 1995
- CALUSER CSCOTT AMACAPINLAC HYEH SROSENFELT NFARID BABDEL-DAYEM HMLARSON SMKALAIGIAN H. Extramedullary Hematopoiesis Assessment in a Patient With Osteopetrosis. Clinical Nuclear Medicine. 20:75-75. 1995
- Scott AMMacapinlac HZhang JDaghighian FMontemayor NKalaigian HSgouros GGraham MCKolbert KYeh SDJLai EGoldsmith SJLarson SM. Image registration of SPECT and CT images using an external fiduciary band and three-dimensional surface fitting in metastatic thyroid cancer. Journal of Nuclear Medicine. 36:100-103. 1995
- Divgi CRScott AMDantis LCapitelli PSiler KHilton SFinn RDKemeny NKelsen DKostakoglu LSchlom JLarson SM. Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma. Journal of Nuclear Medicine. 36:586-592. 1995
- Schneider JADivgi CRScott AMMacapinlac HASeidman ADGoldsmith SJLarson SM. Flare on bone scintigraphy following Taxol chemotherapy for metastatic breast cancer. Journal of Nuclear Medicine. 35:1748-1752. 1994
- Caluser CAbdel-Dayem HMacapinlac HScott AHealey JHuvos AKalaigian HYeh SLarson S. The value of thallium and three-phase bone scans in the evaluation of bone and soft tissue sarcomas. European Journal of Nuclear Medicine and Molecular Imaging. 21:1198-1205. 1994
- Welt SDivgi CRKemeny NFinn RDScott AMGraham MGermain JSRichards ECLarson SMOettgen HF. Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer.. Journal of Clinical Oncology. 12:1561-1571. 1994
- Scott AMMacapinlac HZhang JJKalaigian HGraham MCDivgi CRSgouros GGoldsmith SJLarson SM. Clinical applications of fusion imaging in oncology. Nuclear Medicine and Biology. 21:775-784. 1994
- Larson SMDivgi CScott ADaghighian FMacapinlac HWelt S. Current status of radioimmunodetection. Nuclear Medicine and Biology. 21:721-729. 1994
- Larson SMDivgi CRScott ASgouros GGraham MCKostakoglu LScheinberg DCheung N-KVSchlom JFinn RD. Current status of radioimmunotherapy. Nuclear Medicine and Biology. 21:785-792. 1994
- Macapinlac HAScott AMLarson SMDivgi CRYeh SDJGoldsmith SJ. Gallium-67-citrate imaging in nuclear oncology. Nuclear Medicine and Biology. 21:731-738. 1994
- Welt SDivgi CRScott AMGarin-Chesa PFinn RDGraham MCarswell EACohen ALarson SMOld LJ. Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts.. Journal of Clinical Oncology. 12:1193-1203. 1994
- Tennant CMihailidou AScott ASmith RKellow JJones MHunyor SLorang MHoschl R. Psychological symptom profiles in patients with chest pain. Journal of Psychosomatic Research. 38:365-371. 1994
- Caron PCJurcic JGScott AMFinn RDDivgi CRGraham MCJureidini IMSgouros GTyson DOld LJLarson SMScheinberg DA. A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: Specific targeting without immunogenicity. Blood. 83:1760-1768. 1994
- Larson SMDivgi CRScott AM. Overview of clinical radioimmunodetection of human tumors. Cancer. 73:832-835. 1994
- Divgi CRScott AMMcDermott KFallone PSHilton SSiler KCarmichael NDaghighian FFinn RDCohen AMSchlom JLarson SM. Clinical comparison of radiolocalization of two monoclonal antibodies (mAbs) against the TAG-72 antigen. Nuclear Medicine and Biology. 21:9-15. 1994
- Scott AMMacapinlac HADivgi CRZhang JJKalaigian HPentlow KHilton SGraham MCSgouros GPelizzari CChen GSchlom JGoldsmith SJLarson SM. Clinical validation of SPECT and CT/MRI image registration in radiolabeled monoclonal antibody studies of colorectal carcinoma. Journal of Nuclear Medicine. 35:1976-1984. 1994
- Tjuvajev JGMacapinlac HADaghighian FScott AMGinos JZFinn RDKothari PDesai RZhang JBeattie BGraham MLarson SMBlasberg RG. Imaging of brain tumor proliferative activity with iodine-131- iododeoxyuridine. Journal of Nuclear Medicine. 35:1407-1417. 1994
- Kostakoglu LDivgi CRHilton SCordon-Cardo CScott AMKalaigian HFinn RDSchlom JLarson SM. Preselection of Patients with High TAG-72 Antigen Expression Leads to Targeting of 94% of Known Metastatic Tumor Sites with Monoclonal Antibody I-131-CC49. Cancer Investigation. 12:551-558. 1994
- Abdel-Dayem HScott AMacapinlac HLarson S. Tracer imaging in lung cancer. European Journal of Nuclear Medicine and Molecular Imaging. 21:57-81. 1994
- Scott AMKellow JEShuter BCowan HCorbett AMRiley JWLunzer MREckstein RPHöschl RLam SKJones MP. Intragastric distribution and gastric emptying of solids and liquids in functional dyspepsia - Lack of influence of symptom subgroups and H. pylori-associated gastritis. Digestive Diseases and Sciences. 38:2247-2254. 1993
- SCHNEIDER JADIVGI CRSCOTT AMMACAPINLAC HASONENBERG MGOLDSMITH SJLARSON SM. Hiatal Hernia on Whole-Body Radioiodine Survey Mimicking Metastatic Thyroid Cancer. Clinical Nuclear Medicine. 18:751-753. 1993
- Preston SJDiamond TScott ALaurent MR. Methotrexate osteopathy in rheumatic disease.. Annals of the Rheumatic Diseases. 52:582-585. 1993
- Scott AMKellow JEShuter BNolan JMHoschl RJones MP. Effects of cigarette smoking on solid and liquid intragastric distribution and gastric emptying. Gastroenterology. 104:410-416. 1993
- Scott AMihailidou ASmith RKellow JJones MLorang CHunyor SLorang MHoschl RTennant C. Functional Gastrointestinal Disorders in Unselected Patients with Non-Cardiac Chest Pain. Scandinavian Journal of Gastroenterology. 28:585-590. 1993
- Divgi CRMcDermott KGriffin TWJohnson DKSchnobrich KEFallone PSScott AMHilton SCohen AMLarson SM. Lesion-by-lesion comparison of computerized tomography and indium-111- labeled monoclonal antibody C110 radioimmunoscintigraphy in colorectal carcinoma: A multicenter trial. Journal of Nuclear Medicine. 34:1656-1661. 1993
- Larson SMMacapinlac HAScott AMDivgi CR. Recent Achievements in the Development of Radiolabeled Monoclonal Antibodies for Diagnosis, Therapy and Biologic Characterization of Human Tumors. Acta Oncologica. 32:709-715. 1993
- Scott AMLarson SM. Tumor imaging and therapy. Radiologic Clinics of North America. 31:859-880. 1993
- Scott AMKellow JEEckersley GMNolan JMJones MP. Cigarette smoking and nicotine delay postprandial mouth-cecum transit time. Digestive Diseases and Sciences. 37:1544-1547. 1992
- Scott AMKostakoglu LO'Brien JPStraus DJAbdel-Dayem HMLarson SM. Comparison of technetium-99m-MIBI and thallium-201-chloride uptake in primary thyroid lymphoma. Journal of Nuclear Medicine. 33:1396-1398. 1992
- Bennett EJKellow JECowan HScott AMShuter BLangeluddecke PMHoschl RJones MPTennant CC. Suppression of Anger and Gastric Emptying in Patients with Functional Dyspepsia. Scandinavian Journal of Gastroenterology. 27:869-874. 1992
-
case study
- Tan GJSLee STBerlangieri SUScott AM. Periarticular FDG uptake on PET/CT in malignant melanoma-metastatic or misleading?. Annals of the Academy of Medicine, Singapore. 159-160. 2013
-
chapter
- Scott AMCiprotti MLee ST. Diagnostic applications of nuclear medicine: Malignant melanoma. 1065-1102. 2017
- Scott AMCiprotti MLee ST. Malignant melanoma.. 635-661. 2013
- Agostino MFarrugia WSandrin MSScott AMYuriev ERamsland PA. Structural glycobiology of antibody recognition in xenotransplantation and cancer immunotherapy. 203-228. 2012
- Scott AMLee ST. Clinical radionuclide therapy. 349-385. 2008
-
comment
- Bailey DLHofman MSForwood NJO'Keefe GScott AMvan Wyngaardt WMHowe BKovacev OFrancis RJ. Accuracy of Dose Calibrators for 68 Ga PET Imaging: Unexpected Findings in a Multicenter Clinical Pretrial Assessment. Journal of Nuclear Medicine. 636-638. 2018
-
conference paper
- Owen CMcMaster CLiew DLeung JScott ABuchanan R. Neutrophil to Lymphocyte Ratio Predicts Glucocorticoid Resistance in Polymyalgia Rheumatica. Arthritis and Rheumatology. 2018
- Owen CEMartin EPoon AMLeung JLLiew DFLee STScott AMBuchanan RR. 18F-FDG WHOLE BODY PET/CT AS A DIAGNOSTIC TEST FOR POLYMYALGIA RHEUMATICA IN PATIENTS WITH NORMAL INFLAMMATORY MARKERS. Annals of the Rheumatic Diseases. 1480-1480. 2018
- Owen CEPoon AMYap LPLeung JLLiew DFLee STScott AMBuchanan RR. FIRST DOCUMENTATION OF RS3PE AFFECTING THE HANDS ON 18F-FDG WHOLE BODY PET/CT IN POLYMYALGIA RHEUMATICA. Annals of the Rheumatic Diseases. 1479-1480. 2018
- Wichmann CParslow AAckermann URigopoulos AScott AMWhite J. DEVELOPMENT OF MTORC1 SPECIFIC AGENTS FOR EVALUATION OF HER2 TARGETED THERAPY USING PET. Internal Medicine Journal. 13-13. 2018
- Lee SLee STPoon ABerlangieri SUScott AM. EVALUATION OF CLINICAL RISK FACTORS WHICH MAY PREDICT REGIONAL, NODAL AND METASTATIC DISEASE ON (68)GA-PSMA PET/CT. Internal Medicine Journal. 14-14. 2018
- McDonald AParslow AGoh YWWhite JScott AMAckermann U. HARNESSING ANALOGUES OF THE ONCRASIN-1 FOR RADIOTRACER IMAGING OF TARGETED THERAPY RESISTANCE. Internal Medicine Journal. 12-13. 2018
- Chia PLCao DGan HRigopoulos ARiley EPhillips AJohn TScott A. ABT-806 Derived Antibody Drug Conjugates (ADCs) Inhibit Growth of Malignant Mesothelioma In-Vivo. Journal of Thoracic Oncology. S745-S745. 2018
- Chia PLRussell PAsadi KMurone CWalkiewicz MEriksson UScott AJohn T. Analysis of Angiogenic and Stromal Biomarkers in a Large Malignant Mesothelioma Cohort. Journal of Thoracic Oncology. S399-S399. 2018
- Burvenich IJGParakh SLee FTGuo NLiu ZGan HKRigopoulos AO'Keefe GJGong SJGoh YWTochon-Danguy HScott FEKotsuma MHirotani KSenaldi GScott AM. Molecular imaging of T cell co-regulator factor B7-H3 with 89 Zr-DS-5573a. Theranostics. 4199-4209. 2018
- Burvenich IParakh SLee F-TTGuo NYLiu ZGan HRigopoulos AO'Keefe GJGong SJGoh YWScott FKotsuma MHirotani KSenaldi GScott A. PET/MRI with Zr-89-Df-Bz-NCS-Df-DS-5573a as a theranostic approach. European Journal of Nuclear Medicine and Molecular Imaging. S639-S640. 2018
- Wichmann CParslow ARigopoulos AAckermann UWhite JMScott A. Preclinical evaluation of a mTOR specific PET ligand in a RAD001 sensitive/resistant breast cancer model system. European Journal of Nuclear Medicine and Molecular Imaging. S190-S191. 2018
- Thorne AHBinder ZABakas SWileyto EPMorrissette JJDAkbari HRathore SScott ADavatzikos CO'Rourke DFurnari F. EGFR EXTRACELLULAR DOMAIN POINT MUTANT A289V: A THERAPEUTICALLY TARGETABLE DRIVER OF GLIOBLASTOMA INVASION. Neuro-Oncology. 85-85. 2017
- Lassman ARoberts-Rapp LHe LLu Xvan den Bent MPapadopoulos KMerrell RKumthekar PReardon DGomez EFischer JJiang FZha ZBhathena AHolen KAnsell PGan HKScott A. MOLECULAR DETERMINANTS ASSOCIATED WITH RESPONSE AND RESISTANCE TO DEPATUXIZUMAB MAFODOTIN (ABT-414) IN PATIENTS WITH RECURRENT GLIOBLASTOMA. Neuro-Oncology. 176-177. 2017
- Gan HKBurge MSolomon BLee STHolen KDZhang YCiprotti MLee FTMerdan TMunasinghe WFischer JDAnsell PFox GXiong HReilly EBHumerickhouse RScott AM. A PHASE 1 AND BIODISTRIBUTION STUDY OF ABT-806I, AN INDIUM-111 RADIOLABELED CONJUGATE OF THE TUMOR-SPECIFIC ANTI-EGFR ANTIBODY ABT-806. Internal Medicine Journal. 13-13. 2017
- McArthur SPerera KThapa BNewman MFancourt TLee SJohn TLim ABerlangieri SScott ADavis GKnight SBarnett S. CORRELATION OF METABOLIC PARAMETERS ON 18F-FDG PET WITH PATHOLOGICAL RESPONSE AND OVERALL SURVIVAL IN PATIENTS WITH PANCOAST TUMOURS TREATED WITH TRIMODALITY THERAPY. Internal Medicine Journal. 6-6. 2017
- Baker LPathmaraj KLee STScott A. FDG PET/CT SCAN LENDS CLARITY IN MANAGEMENT OF PATIENT DIAGNOSIS. Internal Medicine Journal. 33-33. 2017
- Ackermann URigopoulos AJaeger ALO'Keefe GTochon-Danguy HJScott AM. IMAGING OF TG2 ACTIVITY IN BREAST CANCER USING RADIOLABELLED HITOMI PEPTIDES. Internal Medicine Journal. 11-11. 2017
- Berlangieri SUPoon ALee STScott AM. IMPLEMENTATION OF A CLINICAL REPORTING QUALITY ASSURANCE PROGRAM IN A HOSPITAL-BASED PET SERVICE. Internal Medicine Journal. 13-14. 2017
- Burvenich IParakh SBurvenich JGLee F-TGuo NGan HKRigopoulos AO'Keefe GJGong STochon-Danguy HKotsuma MHirotani KSenaldi GScott AM. MOLECULAR IMAGING OF T-CELL CO-REGULATOR FACTOR B7-H3 WITH 89Zr-DS-5573A. Internal Medicine Journal. 20-20. 2017
- Ayati NLee STPoon AMcArthur SAl-Qatawna LPathmaraj KZakavi SRScott AM. SANDOSTATIN LAR THERAPY DIFFERENTIALLY ALTERS Ga-68-DOTATATE UPTAKE IN NORMAL TISSUES AND PRIMARY TUMOURS COMPARED TO METASTATIC LESIONS. Internal Medicine Journal. 13-13. 2017
- Tochon-Danguy HJPoniger SSPanopoulos HSachinidis JScott AM. SOLID TARGET PRODUCED ISOTOPES AT AUSTIN HEALTH: 5 YEARS OF EXPERIENCE. Internal Medicine Journal. 30-30. 2017
- van den Bent MGan HLassman AKumthekar PMerrell RButowski NLwin ZMikkelsen TNabors LPapadopoulos KPenas-Prado MSimes JWalbert TScott AGomez ELee H-JRoberts-Rapp LXiong HBain EHolen KMaag DReardon D. EFFICACY OF A NOVEL ANTIBODY-DRUG CONJUGATE (ADC), ABT-414, AS MONOTHERAPY IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (EGFRamp), RECURRENT GLIOBLASTOMA (rGBM). Neuro-Oncology. 2-2. 2016
- Roberts-Rapp LAnsell PKular RSong MSokolova IGan HKPapadopoulos KPLassman ABMerrell RKumthekar PScott AMGomez EFischer JBhathena AHolen KLai RReardon Dvan den Bent M. Identifying the correct patient (pt) population for ABT-414: Biomarker assays for epidermal growth factor receptor (EGFR) in pts with glioblastoma (GBM). Annals of Oncology. 8-9. 2015
- Mortensen ACSpiegelberg DScott AMLane DPNestor M. Enhancing the effect of radiotherapy in cultured tumour cells using p53 therapy. European Journal of Nuclear Medicine and Molecular Imaging. S429-S430. 2015
- Spiegelberg DMortensen ACSelvaraju RKStenberg JScott ANestor M. Improving EGFR imaging by use of an anti-EGFRvIII monoclonal antibody: characterizations in an in vivo squamous cell carcinoma model. European Journal of Nuclear Medicine and Molecular Imaging. S467-S467. 2015
- Spiegelberg DMortensen ACSelvaraju RKEriksson OStenerlow BScott ANestor M. Molecular imaging of EGFR and EGFRvIII for prediction and response monitoring of HSP90 inhibition in an in vivo squamous cell carcinoma model. European Journal of Nuclear Medicine and Molecular Imaging. S263-S264. 2015
- Scott AMAkhurst TLee FCiprotti MDavis IWeickhardt AGan HKocovski PGuo NMurphy DHicks RLee SO'Keefe GGong SHudson P. Phase I Safety and Biodistribution Study of 124I-PEG-AVP0458 Diabody in Patients with TAG-72 Positive Ovarian and Prostate Cancer. European Journal of Nuclear Medicine and Molecular Imaging. S122-S122. 2015
- Van den Bent MJRoberts-Rapp LAnsell PKular RSong MSokolova IGan HPapadopoulos KPLassman ABMerrell RKumthekar PScott AGomez EFischer JBhathena AHolen KLai RReardon D. 2903 Identifying the correct patient (pt) population for ABT-414: Biomarker assays for epidermal growth factor receptor (EGFR) in pts with glioblastoma (GBM). European Journal of Cancer. S585-S586. 2015
- Smaletz ODiz MDPEDo Carmo CCSabbaga JCunha-Junior GFAzevedo SJMaluf FCBarrios CHCosta RLFontana AGMadrigal VWainstein AJYeda FPAlves VAMoro AMBlasbalg RScott AMHoffman EW. A phase II trial with anti-Lewis-Y monoclonal antibody (hu3S193) for the treatment of platinum resistant/refractory ovarian, fallopian tube and primary peritoneal carcinoma. Gynecologic Oncology. 272-277. 2015
- Poniger SSTochon-Danguy HJPanopoulos HPO'Keefe GJPeake DRasool RScott AM. Automated production of 124I and 64Cu using IBA Terimo and Pinctada metal electroplating and processing modules. AIP Conference Proceedings. 114-119. 2012
- Tochon-Danguy HJPoniger SSSachinidis JIPanopoulos HPScott AM. Implementation of a solid target production facility. AIP Conference Proceedings. 176-180. 2012
- He JO'Keefe GJJones GSaunder TGong SJGeso MScott AM. Evaluation of geometrical sensitivity for respiratory motion gating by GATE and NCAT simulation. Annual International Conference of the IEEE Engineering in Medicine and Biology - Proceedings. 4165-4168. 2007
- He JO'Keefe GJGong SJSaunder TJones GScott AMGeso M. Investigation of respiratory motion gating with geometric sensitivity in allegro PET. IEEE Nuclear Science Symposium Conference Record. 4336-4344. 2007
- He JO'Keefe GJJones GSaunder TGong SJGeso MScott AM. The application of GATE and NCAT to respiratory motion simulation in allegro PET. IEEE Nuclear Science Symposium Conference Record. 2589-2593. 2007
- Kelly MPLee FTTahtis KSmyth FEBrechbiel MWScott AM. Radioimmunotherapy with -Particle-Emitting 213Bi-C-Functionalized trans-Cyclohexyl-Diethylenetriaminepentaacetic Acid-Humanized 3S193 Is Enhanced by Combination with Paclitaxel Chemotherapy. Clinical Cancer Research. 5604s-5612s. 2007
- Gong SJO'Keefe GJRykers KMantle CGunawardana DHRolfo AWada MScott AM. PET/CT rigid-body registration in radiation treatment planning settings: Phantom validation and strategy investigation. Lecture Notes in Computer Science. 222-229. 2006
- Gong SJO'Keefe GJScott AM. Comparison and evaluation of PET/CT image registration. Annual International Conference of the IEEE Engineering in Medicine and Biology - Proceedings. 1599-1603. 2005
- Scott ARigopoulos ALee FT. Enhanced Efficacy of Radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by Inhibition of Epidermal Growth Factor Receptor (EGFR) Signaling with EGFR Tyrosine Kinase Inhibitor AG1478. Clinical Cancer Research. 7080s-7086s. 2005
- Scott A. Current status of positron emission tomography in oncology. Journal of Medical Imaging and Radiation Oncology. 154-162. 2002
- Papenfuss ATO'Keefe GJScott AM. Segmented attenuation correction in whole body PET using neighbourhood EM clustering. IEEE Nuclear Science Symposium and Medical Imaging Conference. 2000
- Scott ABERLANGIERI S. F-18 fluorodeoxyglucose positron emission tomography in the non-invasive staging of non-small cell lung cancer*1. European Journal of Cardio-Thoracic Surgery. S25-S30. 1999
- Catimel BNerrie MLee FTScott AMRitter GWelt SOld LJBurgess AWNice EC. Kinetic analysis of the interaction between the monoclonal antibody A33 and its colonic epithelial antigen by the use of an optical biosensor. A comparison of immobilisation strategies. Journal of Chromatography A. 15-30. 1997
-
editorial article
- Scott A. 2018 SNMMI Highlights Lecture: Oncology and therapy. Journal of Nuclear Medicine. 59:11N-18N. 2018
- Lee STScott AM. Nuclear medicine in the era of personalised medicine. Internal Medicine Journal. 48:497-499. 2018
- Lawrentschuk NCorfield JMScott A. Is choline-based PET imaging still relevant in recurrent prostate cancer?. BJU International. 120:303-304. 2017
- LEE STSCOTT AM. Are we ready for dual-time point FDG PET imaging?. Journal of Medical Imaging and Radiation Oncology. 55:351-352. 2011
-
erratum
- Greening DWLee STJi HSimpson RJRigopoulos AMurone CFang CGong SO’Keefe GScott AM. Correction: Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathways. Oncotarget. 35497. 2016
-
abstract
- Scott ABurvenich ILee FO'Keefe GMakris DCao DGong SRigopoulos AAllan LBrechbiel MLiu ZRamsland P. Engineering anti-Lewis-Y hu3S193 antibodies with improved therapeutic ratio for radioimmunotherapy of epithelial cancers. Internal Medicine Journal. 19-19. 2016
- Nadebaum DLee SNikfarjam MScott A. METASTATIC CLEAR CELL RENAL CELL CARCINOMA DEMONSTRATING FOCAL UPTAKE ON (68)GA-DOTATATE PET. Internal Medicine Journal. 37-37. 2016
- Gong SJO'Keefe GJLee STAkhurst TLee FTDavis IWeickhardt AGan HPathmeraj KHicks RJHudson PJScott AM. DOSIMETRY OF I-124-PEG-AVP0458 DIABODY IN PATIENTS WITH TAG-72 POSITIVE OVARIAN OR PROSTATE CANCER. Internal Medicine Journal. 40-41. 2015